Anti-human immunodeficiency virus-1 antibodies and their usage
By modifying the light and heavy chain CDR sequences of the anti-HIV-1 antibody, the binding ability to the HIV-1 p24 protein is enhanced, solving the problem of insufficient sensitivity of existing antibodies, achieving high efficiency and accuracy in early HIV-1 detection, and supporting the application of various immunoassays and blood screening platforms.
Patent Information
- Application Number
- CN202611288865.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2020-07-13
- Filing Date
- 2021-07-13
- Publication Date
- 2026-11-17
AI Technical Summary
Existing HIV-1 p24 antibody tests have low sensitivity, making it difficult to detect HIV-1 infection in its early stages and failing to meet the needs for rapid diagnosis and prevention of secondary transmission.
A novel anti-HIV-1 antibody has been developed that enhances the binding affinity to the HIV-1 p24 protein through modified light and heavy chain complementarity-determining region (CDR) sequences, including amino acid sequence variations of L-CDR1, L-CDR2, L-CDR3 and H-CDR1, H-CDR2, and H-CDR3, thereby improving the antibody's specificity and sensitivity.
It improves the binding ability of antibodies to HIV-1 p24 protein, shortens the diagnostic window period, enhances the sensitivity and accuracy of early HIV-1 detection, and supports the application of various immunoassay and blood screening platforms.
Smart Images

Figure CN123106892A_ABST
Abstract
Description
[0001] This application is a divisional application of the application filed on July 13, 2021, with application number 202180049156.7 and invention title "Anti-human Immunodeficiency Virus-1 Antibody and Method of Using Thereof". Technical Field
[0002] This application relates to antibodies against human immunodeficiency virus-1 (anti-HIV-1) that specifically bind to the HIV-1 p24 protein. The invention also relates to methods and assays for detecting HIV-1 in samples using said antibodies. background Human immunodeficiency virus 1 (HIV-1) is a retrovirus that infects 37.9 million people worldwide and causes approximately 1 million deaths annually, particularly among vulnerable populations who lack access to diagnosis and treatment. Soliman, M. et al. Mechanisms of HIV Control. Current HIV / AIDS Reports 2017, vol. 14(3);101-9 HIV-1 is the leading cause of acquired immunodeficiency syndrome (AIDS), an incurable disease transmitted through sexual contact with an HIV-1 infected person or through exposure to blood or blood-derived products. The virus targets the immune system by destroying and weakening the function of immune cells. Infected individuals become immunodeficient and susceptible to other opportunistic infections and certain types of cancer. WHO website source - https: / / www.who.int / news-room / fact-sheets / detail / hiv-aids Currently, only 46% of individuals living with HIV-1 are aware of their infection status. Therefore, HIV-1 testing in acute infections is an important public health issue. Stone, M. et al. Comparison of detection limits of fourth- and fifth-generation combination HIV antigen- antibody, p24 antigen, and viral load assays on diverse HIV isolates. Journal of Clinical Microbiology 2018, vol. 56(8);1-12).
[0003] In this specific context, the goal is to diagnose HIV-1 immediately within weeks of an individual's infection (acute phase), which may prevent secondary transmission and allow for early access to treatment and care. Lewis J. et al. Field accuracy of fourth-generation rapid diagnostic tests for acute HIV-1: a systematic review. AIDS 2015, vol. 29(18);2465-71 To achieve this goal promptly, HIV-1 detection using early biomarkers is crucial. The most commonly used biomarkers for diagnosing HIV-1 infection are antibodies against viral structural proteins. Here, p24 is considered an important biomarker for early HIV-1 detection because it is the most abundant structural protein in the HIV-1 viral envelope and is secreted at high levels in serum during the initial stages of infection. p24 is a polymeric capsid protein that acts as a major structural component of the HIV-1 envelope surrounding the viral RNA molecule. p24 is a 24-25 kDa protein derived from the Gag polyprotein precursor and, like HIV-1 RNA, can be detected before serum conversion.Gray, E.R. et al. p24 revisited: a landscape review of antigen detection for early HIV diagnosis. AIDS. 2018, vol.32(15);2089-102 ).
[0004] Current guidelines from the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) recommend the use of fourth-generation antibody-antigen assays as the preferred method for HIV-1 screening. These tests detect the p24 antigen and anti-HIV-1 antibodies, and shorten the diagnostic window period from 4 weeks after exposure to 2 weeks. Gray, E.R. et al. p24 revisited: a landscape review of antigen detection for early HIV diagnosis. AIDS. 2018, vol. 32(15); 2089-102; Codoner, F. et al. Gag protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors. Scientific Reports 2017, vol. 7(3717);1-10; Alexander TS. Human Immunodeficiency Virus Diagnostic Testing: 30 Years of Evolution. Clinical and Vaccine Immunology 2016, vol. 23(4);249-53; WHO. World Health Organization Model List of Essential In Vitro Diagnostics. 1st Edition Geneva.2018; Centers for Disease Control and Prevention. 2017. National HIV testing day and new testing recommendations. Morbidity and Mortality Weekly Report vol. 63(25);537-37 ).
[0005] However, there is still a need for anti-HIV-1 antibodies that specifically bind to the p24 antigen and have high binding capacity and good manufacturing characteristics, because some commercially available antibodies currently have low sensitivity for early p24 detection.
[0006] Therefore, the present invention provides anti-HIV-1 antibodies with modified binding ability against the HIV-1 p24 protein compared to similar commercial reagents. These antibodies recognize novel, non-cross-reactive epitopes and can be used as standalone entities or capture / detect partners in a variety of HIV-1 immunoassays, such as immunodiagnostics or blood screening platforms.
[0007] Overview When this specification refers to a sequence of CDR X or a sequence differing from CDR X by one or two substitutions, deletions, or additions, it should be understood that such substitutions, deletions, or additions can occur at any amino acid within the amino acid range defined by CDR X. This specification individualizes each specific amino acid within the amino acid range defined by CDR X to suit such substitutions, deletions, or additions.
[0008] By way of non-limiting illustration, L-CDR1 of antibody #A can be defined as a sequence containing amino acids (1)-(11), RASQDISNYLH [as shown in SEQ ID NO: 15]. Unless otherwise specified or subsequently improved by modification, each of positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11 is considered suitable for substitution, deletion or addition.
[0009] In a first aspect, the present invention discloses an anti-HIV-1 antibody comprising a light chain, the light chain comprising complementarity-determining regions L-CDR1, L-CDR2, and L-CDR3, wherein the amino acid sequence of L-CDR1 is selected from SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, and sequences differing from any one of SEQ ID NO: 15, 18, or 21 by one or two substitutions, deletions, or additions; the amino acid sequence of L-CDR2 is selected from SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22, and sequences differing from any one of SEQ ID NO: 16, 19, or 22 by one or two substitutions, deletions, or additions; and the amino acid sequence of L-CDR3 is selected from SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, and sequences differing from any one of SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 21, and sequences differing from any one of SEQ ID NO: 21 by one or two substitutions, deletions, or additions; and the amino acid sequence of L-CDR3 is selected from SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, and sequences differing from any one of SEQ ID NO: 20, SEQ ID NO: 21 by one or two substitutions, deletions, or additions. A group consisting of any one of 17, 20, or 23 that differs by one or two substitutions, deletions, or additions.
[0010] In other embodiments, the anti-HIV-1 antibody of the present invention comprises a heavy chain including complementarity-determining regions H-CDR1, H-CDR2, and H-CDR3, wherein the amino acid sequence of H-CDR1 is selected from the group consisting of SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30 and sequences differing from any one of SEQ ID NO: 24, 27, or 30 by one or two substitutions, deletions, or additions; the amino acid sequence of H-CDR2 is selected from the group consisting of SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 31 and sequences differing from any one of SEQ ID NO: 25, 28, or 31 by one or two substitutions, deletions, or additions; and the amino acid sequence of H-CDR3 is selected from the group consisting of SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32 and sequences differing from any one of SEQ ID NO: 26, 29, or 32 by one or two substitutions, deletions, or additions.
[0011] In some embodiments, the light chain of the anti-HIV-1 antibody of the present invention comprises a sequence having approximately 90% homology with the following amino acid sequence: SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9. In other embodiments, the light chain comprises the following amino acid sequence: SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9.
[0012] In some embodiments, the heavy chain of the anti-HIV-1 antibody of the present invention comprises a sequence having approximately 90% homology with the following amino acid sequence: SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12. In other embodiments, the heavy chain comprises the following amino acid sequence: SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12.
[0013] In some embodiments, the amino acid sequence of L-CDR1 includes SEQ ID NO: 15 or a sequence differing from SEQ ID NO: 15 by one or two substitutions, deletions, or additions; the amino acid sequence of L-CDR2 includes SEQ ID NO: 16 or a sequence differing from SEQ ID NO: 16 by one or two substitutions, deletions, or additions; and the amino acid sequence of L-CDR3 includes SEQ ID NO: 17 or a sequence differing from SEQ ID NO: 17 by one or two substitutions, deletions, or additions. In other embodiments, the amino acid sequence of L-CDR1 includes SEQ ID NO: 18 or a sequence differing from SEQ ID NO: 18 by one or two substitutions, deletions, or additions; the amino acid sequence of L-CDR2 includes SEQ ID NO: 19 or a sequence differing from SEQ ID NO: 19 by one or two substitutions, deletions, or additions; and the amino acid sequence of L-CDR3 includes SEQ ID NO: 20 or a sequence differing from SEQ ID NO: 20 by one or two substitutions, deletions, or additions. In other embodiments, the amino acid sequence of L-CDR1 includes SEQ ID NO: 21 or differs from SEQ ID NO: 21 by one or two substitutions, deletions, or additions; the amino acid sequence of L-CDR2 includes SEQ ID NO: 22 or differs from SEQ ID NO: 22 by one or two substitutions, deletions, or additions; and the amino acid sequence of L-CDR3 includes SEQ ID NO: 23 or differs from SEQ ID NO: 23 by one or two substitutions, deletions, or additions.
[0014] In some embodiments, the amino acid sequence of H-CDR1 includes SEQ ID NO: 24 or a sequence differing from SEQ ID NO: 24 by one or two substitutions, deletions, or additions; the amino acid sequence of H-CDR2 includes SEQ ID NO: 25 or a sequence differing from SEQ ID NO: 25 by one or two substitutions, deletions, or additions; and the amino acid sequence of H-CDR3 includes SEQ ID NO: 26 or a sequence differing from SEQ ID NO: 26 by one or two substitutions, deletions, or additions. In other embodiments, the amino acid sequence of H-CDR1 includes SEQ ID NO: 27 or a sequence differing from SEQ ID NO: 27 by one or two substitutions, deletions, or additions; the amino acid sequence of H-CDR2 includes SEQ ID NO: 28 or a sequence differing from SEQ ID NO: 28 by one or two substitutions, deletions, or additions; and the amino acid sequence of H-CDR3 includes SEQ ID NO: 29 or a sequence differing from SEQ ID NO: 29 by one or two substitutions, deletions, or additions. In other embodiments, the amino acid sequence of H-CDR1 includes SEQ ID NO: 30 or differs from SEQ ID NO: 30 by one or two substitutions, deletions, or additions; the amino acid sequence of H-CDR2 includes SEQ ID NO: 31 or differs from SEQ ID NO: 31 by one or two substitutions, deletions, or additions; and the amino acid sequence of H-CDR3 includes SEQ ID NO: 32 or differs from SEQ ID NO: 32 by one or two substitutions, deletions, or additions.
[0015] In some embodiments, the amino acid sequence of L-CDR1 includes SEQ ID NO: 15 or differs from SEQ ID NO: 15 by one or two substitutions, deletions, or additions; the amino acid sequence of L-CDR2 includes SEQ ID NO: 16 or differs from SEQ ID NO: 16 by one or two substitutions, deletions, or additions; the amino acid sequence of L-CDR3 includes SEQ ID NO: 17 or differs from SEQ ID NO: 17 by one or two substitutions, deletions, or additions; the amino acid sequence of H-CDR1 includes SEQ ID NO: 24 or differs from SEQ ID NO: 24 by one or two substitutions, deletions, or additions; the amino acid sequence of H-CDR2 includes SEQ ID NO: 25 or differs from SEQ ID NO: 25 by one or two substitutions, deletions, or additions; and the amino acid sequence of H-CDR3 includes SEQ ID NO: 26 or differs from SEQ ID NO: 26 by one or two substitutions, deletions, or additions.
[0016] In some embodiments, the amino acid sequence of L-CDR1 includes SEQ ID NO: 18 or differs from SEQ ID NO: 18 by one or two substitutions, deletions, or additions; the amino acid sequence of L-CDR2 includes SEQ ID NO: 19 or differs from SEQ ID NO: 19 by one or two substitutions, deletions, or additions; the amino acid sequence of L-CDR3 includes SEQ ID NO: 20 or differs from SEQ ID NO: 20 by one or two substitutions, deletions, or additions; the amino acid sequence of H-CDR1 includes SEQ ID NO: 27 or differs from SEQ ID NO: 27 by one or two substitutions, deletions, or additions; the amino acid sequence of H-CDR2 includes SEQ ID NO: 28 or differs from SEQ ID NO: 28 by one or two substitutions, deletions, or additions; and the amino acid sequence of H-CDR3 includes SEQ ID NO: 29 or differs from SEQ ID NO: 29 by one or two substitutions, deletions, or additions.
[0017] In some embodiments, the amino acid sequence of L-CDR1 includes SEQ ID NO: 21 or differs from SEQ ID NO: 21 by one or two substitutions, deletions, or additions; the amino acid sequence of L-CDR2 includes SEQ ID NO: 22 or differs from SEQ ID NO: 22 by one or two substitutions, deletions, or additions; the amino acid sequence of L-CDR3 includes SEQ ID NO: 23 or differs from SEQ ID NO: 23 by one or two substitutions, deletions, or additions; the amino acid sequence of H-CDR1 includes SEQ ID NO: 30 or differs from SEQ ID NO: 30 by one or two substitutions, deletions, or additions; the amino acid sequence of H-CDR2 includes SEQ ID NO: 31 or differs from SEQ ID NO: 31 by one or two substitutions, deletions, or additions; and the amino acid sequence of H-CDR3 includes SEQ ID NO: 32 or differs from SEQ ID NO: 32 by one or two substitutions, deletions, or additions.
[0018] In some embodiments, the light chain of the anti-HIV-1 antibody of the present invention comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3.
[0019] In some embodiments, the heavy chain of the anti-HIV-1 antibody of the present invention comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6.
[0020] In some embodiments, the anti-HIV-1 antibody of the present invention specifically binds to an epitope of the HIV-1 p24 protein containing the amino acid sequence of SEQ ID NO: 33.
[0021] In some embodiments, the amino acid sequence of L-CDR1 of the anti-HIV-1 antibody of the present invention comprises SEQ ID NO: 21 or differs from SEQ ID NO: 21 by one or two substitutions, deletions, or additions; the amino acid sequence of L-CDR2 comprises SEQ ID NO: 22 or differs from SEQ ID NO: 22 by one or two substitutions, deletions, or additions; and the amino acid sequence of L-CDR3 comprises SEQ ID NO: 23 or differs from SEQ ID NO: 23 by one or two substitutions, deletions, or additions.
[0022] In some embodiments, the amino acid sequence of H-CDR1 of the anti-HIV-1 antibody of the present invention comprises SEQ ID NO: 30 or differs from SEQ ID NO: 30 by one or two substitutions, deletions, or additions; the amino acid sequence of H-CDR2 comprises SEQ ID NO: 31 or differs from SEQ ID NO: 31 by one or two substitutions, deletions, or additions; and the amino acid sequence of H-CDR3 comprises SEQ ID NO: 32 or differs from SEQ ID NO: 32 by one or two substitutions, deletions, or additions.
[0023] In some preferred embodiments, the light chain of the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, and the heavy chain of the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6.
[0024] In some embodiments, the anti-HIV-1 antibody of the present invention is a monoclonal antibody or a recombinant antibody. In other embodiments, the antibody is an antibody fragment. When the anti-HIV-1 antibody is an antibody fragment, it is selected from variable fragments (Fv), single-chain Fv (scFv), bispecific antibodies (sc(Fv)2), single-chain antibodies, single-domain antibodies, Fab fragments, F(ab')2 fragments, Fab' fragments, disulfide-linked Fv (dsFv), chemically conjugated Fv (ccFv), diabodies, anti-idiotypic (anti-Id) antibodies, affibodies, nanobodies, and unibodies.
[0025] In some implementations, the anti-HIV-1 antibody contains a constant region of mouse IgG1 or mouse IgG2a.
[0026] In some implementations, the anti-HIV-1 antibody is bound to a solid support.
[0027] In some aspects, the present invention discloses a cell comprising the anti-HIV-1 antibody of the present invention.
[0028] In other aspects, the present invention discloses a nucleic acid comprising a nucleotide sequence encoding an anti-HIV-1 antibody, a promoter operatively linked to said nucleotide sequence, and a selectable marker. The present invention also discloses a cell comprising said nucleic acid.
[0029] The present invention also discloses compositions comprising an anti-HIV-1 antibody as described herein and a solid support, wherein the anti-HIV-1 antibody is covalently or non-covalently bound to the solid support. In some embodiments, the solid support comprises a solid phase of particles, beads, membranes, surfaces, peptide chips, microtiter plates, or chromatographic columns.
[0030] The present invention also discloses a kit for detecting the presence of HIV-1 in a sample, the kit comprising at least one anti-HIV-1 antibody according to the present invention and a solid support, wherein the at least one antibody is covalently or non-covalently bound to the solid support.
[0031] This application provides the following: 1. An anti-HIV-1 antibody comprising a light chain, said light chain comprising a complementarity-determining region (L-CDR1), a complementarity-determining region (L-CDR2), and a complementarity-determining region (L-CDR3), wherein... The amino acid sequence of L-CDR1 is selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21 and sequences differing from any one of SEQ ID NO: 15, 18 and 21 by one or two substitutions, deletions or additions. The amino acid sequence of L-CDR2 is selected from SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22 and the group consisting of sequences that differ from any one of SEQ ID NO: 16, 19 and 22 by one or two substitutions, deletions or additions. The amino acid sequence of L-CDR3 is selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23 and sequences that differ from any one of SEQ ID NO: 17, 20 and 23 by one or two substitutions, deletions or additions.
[0032] 2. The anti-HIV-1 antibody according to Project 1, wherein the antibody comprises a heavy chain, the heavy chain comprising a complementarity-determining region H-CDR1, a complementarity-determining region H-CDR2, and a complementarity-determining region H-CDR3, wherein... The amino acid sequence of H-CDR1 is selected from the group consisting of SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30 and sequences differing from any one of SEQ ID NO: 24, 27 and 30 by one or two substitutions, deletions or additions. The amino acid sequence of H-CDR2 is selected from SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 31 and the group consisting of sequences differing from any one of SEQ ID NO: 25, 28 and 31 by one or two substitutions, deletions or additions, and The amino acid sequence of H-CDR3 is selected from the group consisting of SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32 and sequences that differ from any one of SEQ ID NO: 26, 29 and 32 by one or two substitutions, deletions or additions.
[0033] 3. The anti-HIV-1 antibody according to any one of the preceding items, wherein the light chain comprises a sequence having approximately 90% homology with the following amino acid sequences: SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9.
[0034] 4. The anti-HIV-1 antibody according to Project 3, wherein the light chain comprises the following amino acid sequences: SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9.
[0035] 5. The anti-HIV-1 antibody according to any one of the preceding items, wherein the heavy chain comprises a sequence having approximately 90% homology with the following amino acid sequences: SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12.
[0036] 6. The anti-HIV-1 antibody according to Item 5, wherein the heavy chain comprises the following amino acid sequences: SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12.
[0037] 7. The anti-HIV-1 antibody according to any one of the preceding items, wherein the amino acid sequence of L-CDR1 comprises SEQ ID NO: 15 or a sequence differing from SEQ ID NO: 15 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR2 contains SEQ ID NO: 16 or differs from SEQ ID NO: 16 by one or two substitutions, deletions, or additions, and The amino acid sequence of L-CDR3 contains SEQ ID NO: 17 or differs from SEQ ID NO: 17 by one or two substitutions, deletions, or additions.
[0038] 8. An anti-HIV-1 antibody according to any one of items 1 to 6, wherein the amino acid sequence of L-CDR1 comprises SEQ ID NO: 18 or a sequence differing from SEQ ID NO: 18 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR2 contains SEQ ID NO: 19 or differs from SEQ ID NO: 19 by one or two substitutions, deletions, or additions, and The amino acid sequence of L-CDR3 contains SEQ ID NO: 20 or differs from SEQ ID NO: 20 by one or two substitutions, deletions, or additions.
[0039] 9. An anti-HIV-1 antibody according to any one of items 1 to 6, wherein the amino acid sequence of L-CDR1 includes SEQ ID NO: 21 or a sequence differing from SEQ ID NO: 21 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR2 contains SEQ ID NO: 22 or differs from SEQ ID NO: 22 by one or two substitutions, deletions, or additions, and The amino acid sequence of L-CDR3 contains SEQ ID NO: 23 or differs from SEQ ID NO: 23 by one or two substitutions, deletions, or additions.
[0040] 10. An anti-HIV-1 antibody according to any one of items 1 to 7, wherein the amino acid sequence of H-CDR1 comprises SEQ ID NO: 24 or a sequence differing from SEQ ID NO: 24 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR2 contains SEQ ID NO: 25 or differs from SEQ ID NO: 25 by one or two substitutions, deletions, or additions, and The amino acid sequence of H-CDR3 contains SEQ ID NO: 26 or differs from SEQ ID NO: 26 by one or two substitutions, deletions, or additions.
[0041] 11. An anti-HIV-1 antibody according to any one of items 1 to 6 or 8, wherein the amino acid sequence of H-CDR1 comprises SEQ ID NO: 27 or differs from SEQ ID NO: 27 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR2 contains SEQ ID NO: 28 or differs from SEQ ID NO: 28 by one or two substitutions, deletions, or additions, and The amino acid sequence of H-CDR3 contains SEQ ID NO: 29 or differs from SEQ ID NO: 29 by one or two substitutions, deletions, or additions.
[0042] 12. An anti-HIV-1 antibody according to any one of items 1 to 6 or 9, wherein the amino acid sequence of H-CDR1 comprises SEQ ID NO: 30 or differs from SEQ ID NO: 30 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR2 contains SEQ ID NO: 31 or differs from SEQ ID NO: 31 by one or two substitutions, deletions, or additions, and The amino acid sequence of H-CDR3 contains SEQ ID NO: 32 or differs from SEQ ID NO: 32 by one or two substitutions, deletions, or additions.
[0043] 13. An anti-HIV-1 antibody according to any one of items 1 to 6, wherein the amino acid sequence of L-CDR1 comprises SEQ ID NO: 15 or differs from SEQ ID NO: 15 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR2 contains SEQ ID NO: 16 or differs from SEQ ID NO: 16 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR3 contains SEQ ID NO: 17 or differs from SEQ ID NO: 17 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR1 contains SEQ ID NO: 24 or differs from SEQ ID NO: 24 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR2 contains SEQ ID NO: 25 or differs from SEQ ID NO: 25 by one or two substitutions, deletions, or additions, and The amino acid sequence of H-CDR3 contains SEQ ID NO: 26 or differs from SEQ ID NO: 26 by one or two substitutions, deletions, or additions.
[0044] 14. An anti-HIV-1 antibody according to any one of items 1 to 6, wherein the amino acid sequence of L-CDR1 comprises SEQ ID NO: 18 or differs from SEQ ID NO: 18 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR2 contains SEQ ID NO: 19 or differs from SEQ ID NO: 19 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR3 contains SEQ ID NO: 20 or differs from SEQ ID NO: 20 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR1 contains SEQ ID NO: 27 or differs from SEQ ID NO: 27 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR2 contains SEQ ID NO: 28 or differs from SEQ ID NO: 28 by one or two substitutions, deletions, or additions, and The amino acid sequence of H-CDR3 contains SEQ ID NO: 29 or differs from SEQ ID NO: 29 by one or two substitutions, deletions, or additions.
[0045] 15. An anti-HIV-1 antibody according to any one of items 1 to 6, wherein the amino acid sequence of L-CDR1 comprises SEQ ID NO: 21 or a sequence differing from SEQ ID NO: 21 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR2 contains SEQ ID NO: 22 or differs from SEQ ID NO: 22 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR3 contains SEQ ID NO: 23 or differs from SEQ ID NO: 23 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR1 contains SEQ ID NO: 30 or differs from SEQ ID NO: 30 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR2 contains SEQ ID NO: 31 or differs from SEQ ID NO: 31 by one or two substitutions, deletions, or additions, and The amino acid sequence of H-CDR3 contains SEQ ID NO: 32 or differs from SEQ ID NO: 32 by one or two substitutions, deletions, or additions.
[0046] 16. An anti-HIV-1 antibody according to any one of items 1 to 6, wherein the light chain of said antibody comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3.
[0047] 17. An anti-HIV-1 antibody according to any one of items 1 to 6, wherein the heavy chain of said antibody comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6.
[0048] 18. An anti-HIV-1 antibody according to any one of items 1 to 6, wherein the light chain of the antibody comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, and the heavy chain of the antibody comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6.
[0049] 19. An anti-HIV-1 antibody according to any one of the preceding items, wherein the antibody is a monoclonal antibody or a recombinant antibody.
[0050] 20. An anti-HIV-1 antibody according to any one of the preceding items, wherein the antibody is an antibody fragment.
[0051] 21. The anti-HIV-1 antibody according to Item 20, wherein the antibody fragment is selected from variable fragments (Fv), single-chain Fv (scFv), bispecific antibodies (sc(Fv)2), single-chain antibodies, single-domain antibodies, Fab fragments, F(ab')2 fragments, Fab' fragments, disulfide-linked Fv (dsFv), chemically conjugated Fv (ccFv), biantibodies, anti-idiotype (anti-Id) antibodies, affinity molecules, nanobodies, and monoantibodies.
[0052] 22. The anti-HIV-1 antibody according to any one of the preceding items, wherein the antibody comprises a constant region of mouse IgG1 or mouse IgG2a.
[0053] 23. The anti-HIV-1 antibody according to any one of the preceding items, wherein the antibody is bound to a solid support.
[0054] 24. A cell comprising an anti-HIV-1 antibody as described in any of the preceding items.
[0055] 25. A nucleic acid comprising a nucleotide sequence encoding an anti-HIV-1 antibody according to any one of items 1 to 20; a promoter operatively linked to the nucleotide sequence; and a selection marker.
[0056] 26. A cell comprising the nucleic acid as described in item 25.
[0057] 27. A composition comprising an anti-HIV-1 antibody according to any one of items 1 to 20; and a solid support wherein the anti-HIV-1 antibody is covalently or non-covalently bound to the solid support.
[0058] 28. The composition according to item 27, wherein the solid support comprises the solid phase of particles, beads, membranes, surfaces, peptide chips, microtiter plates, and chromatographic columns.
[0059] 29. A kit for detecting the presence of HIV-1 in a sample, the kit comprising at least one anti-HIV-1 antibody according to any one of items 1 to 23 and a solid support, wherein the at least one anti-HIV-1 antibody is covalently or non-covalently bound to the solid support.
[0060] 30. An anti-HIV-1 antibody, characterized in that the anti-HIV-1 antibody specifically binds to an epitope of the HIV-1 p24 protein, wherein the epitope of the HIV-1 p24 protein comprises the amino acid sequence of SEQ ID NO: 33.
[0061] 31. The anti-HIV-1 antibody according to item 30, wherein the amino acid sequence of L-CDR1 includes SEQ ID NO:21 or differs from SEQ ID NO:21 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR2 contains SEQ ID NO: 22 or differs from SEQ ID NO: 22 by one or two substitutions, deletions, or additions, and The amino acid sequence of L-CDR3 contains SEQ ID NO: 23 or differs from SEQ ID NO: 23 by one or two substitutions, deletions, or additions.
[0062] 32. The anti-HIV-1 antibody according to any one of items 30 to 31, wherein the amino acid sequence of H-CDR1 comprises SEQ ID NO: 30 or differs from SEQ ID NO: 30 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR2 contains SEQ ID NO: 31 or differs from SEQ ID NO: 31 by one or two substitutions, deletions, or additions, and The amino acid sequence of H-CDR3 contains SEQ ID NO: 32 or differs from SEQ ID NO: 32 by one or two substitutions, deletions, or additions. Brief description of the attached diagram Figure 1 SE-UPLC analysis shows the percentage of antibody #A monomers; and SDS-PAGE shows antibody #A monoclonal samples (lanes 1, 2, and 3 represent subclones running under reducing and non-reducing conditions, respectively).
[0063] Figure 2 SE-UPLC analysis shows the percentage of antibody #B monomers; and SDS-PAGE shows antibody #B monoclonal antibodies (lanes 1, 2, and 3 represent subclones running under reducing and non-reducing conditions, respectively).
[0064] Figure 3 SE-UPLC analysis shows the percentage of antibody #D monomers; and SDS-PAGE shows antibody #D monoclonal samples (lanes 1, 2, and 3 represent subclones running under reducing and non-reducing conditions, respectively).
[0065] Figure 4This is a PDB file showing the predicted structures of antibodies #A, #B, and #D (respectively...). Figure 4 A, Figure 4 B and Figure 4 D). For antibody #A, the PDB structural code 2XKN is used for homology lookup, while codes 5OPY and 1F3D are used for antibodies B# and #D, respectively.
[0066] Figure 5 This is a sensory map showing the interaction between saturated antibody #A and competing antibodies #B and #D. Antibodies #B and #D add signals to #A, indicating that these antibodies do not compete for binding within the same epitope region.
[0067] Figure 6 This is a sensory map showing the interaction between saturated antibody #B and competing antibodies #A and #D. Antibodies #A and #D add signals to #B, indicating that these antibodies do not compete for binding in the same epitope region.
[0068] Figure 7 This is a sensory map showing the interaction between saturated antibody #D and competing antibodies #A and #B. Antibodies #A and #B add signals to #D, indicating that these antibodies do not compete for binding in the same epitope region.
[0069] Figure 8 This is a sensor map showing the association of antibodies #A, #B, and #D with HIV-1 p24 in the absence of competing antibodies. Each antibody was shown to have its complete binding signal (experimental control).
[0070] Figure 9 The binding kinetics of antibodies #A, #B, and #D, as well as commercial mAb #1, to the HIV-1 p24 antigen were calculated using biolayer interferometry (BLI). Sensing maps were plotted for concentration gradients from 0.1 to 33 nM, and a 1:1 binding model was fitted to calculate ka (association rate constant), kd (dissociation rate constant), and KD (equilibrium dissociation constant).
[0071] Figure 10 The binding of antibodies #A, #B, and #D, as well as commercial mAb #2, to the HIV-1 p24 capsid protein was measured by indirect ELISA. Titration curves for each antibody were generated starting at a concentration of 2 µg / mL, followed by 1:10 dilutions (left). The signal-to-noise ratio data for a 200 ng / mL antibody concentration are shown on the right, indicating that commercial mAb #2 performs worse than antibodies #A, #B, and #D.
[0072] Detailed Explanation The following description is intended only to illustrate various embodiments of the present disclosure. Therefore, the specific modifications discussed are not intended to be limiting. It will be apparent to those skilled in the art that various equivalents, changes, and modifications can be made without departing from the spirit or scope of the subject matter set forth herein, and it should be understood that such equivalent embodiments are included herein.
[0073] Unless the context clearly specifies otherwise, the singular forms “a”, “an” and “the” as used in this specification and the appended claims include the plural indicator.
[0074] Throughout this specification, unless the context otherwise requires, the word “comprise” or variations such as “comprises” or “comprising” shall be understood to imply inclusion of the stated element or integer or group of elements or integers, but not to exclude any other element or integer or group of elements or integers.
[0075] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Exemplary methods and materials are described below, although similar or equivalent methods and materials may be used and will be apparent to those skilled in the art. All publications and other references mentioned herein are incorporated herein by reference in their entirety. In case of conflict, this specification, including definitions, shall prevail. Materials, methods, and examples are illustrative only and are not intended to be limiting.
[0076] Unless otherwise expressly stated, each embodiment in this specification will be applied to each other embodiment with necessary modifications.
[0077] Unless otherwise stated, the following terms shall be understood to have the following meanings: As used in this article, the term "nucleic acid" refers to any material containing DNA or RNA. Nucleic acids can be synthesized or made from living cells.
[0078] As used herein, a "nucleotide" is a nucleic acid subunit consisting of a phosphate group, a 5-carbon sugar, and a nitrogenous base. The 5-carbon sugar found in RNA is ribose. In DNA, the 5-carbon sugar is 2'-deoxyribose. The term also includes analogues of such subunits.
[0079] As used herein, the term "polynucleotide" refers to a polymeric chain of nucleotides. This term includes DNA molecules (e.g., cDNA, genomic DNA, or synthetic DNA) and RNA molecules (e.g., mRNA or synthetic RNA), as well as DNA or RNA analogs containing non-natural nucleotide analogs, non-natural nucleoside bonds, or both. Nucleic acids can exist in any topological conformation. For example, nucleic acids can be single-stranded, double-stranded, triple-stranded, tetrad, partially double-stranded, branched, hairpin, circular, or padlock conformations.
[0080] As used herein, the term "protein" refers to a large biomolecule or macromolecule consisting of one or more chains of amino acid residues. Many proteins are enzymes that catalyze biochemical reactions and are essential for metabolism. Proteins also have structural or mechanical functions, such as actin and myosin in muscle, and proteins in the cytoskeleton that form the scaffold system that maintains cell shape. Other proteins are important in cell signaling, immune responses, cell adhesion, and the cell cycle. However, proteins can be entirely artificial or recombinant, meaning they are not naturally occurring in biological systems.
[0081] As used herein, the term "peptide" refers to proteins, both naturally occurring and non-natural, as well as their fragments, mutants, derivatives, and analogs. Peptides can be monomeric or polymeric. Peptides can contain many different domains (peptides), each domain possessing one or more different activities.
[0082] As used herein, the term “recombinant” refers to a biomolecule, such as a gene or protein, that (1) has been removed from its naturally occurring environment, (2) is not associated with all or part of the polynucleotide in which the gene is found in nature, (3) is operatively linked to a polynucleotide that is not linked in nature, or (4) is not found in nature. The term “recombinant” may also refer to cloned DNA isolates, chemically synthesized polynucleotide analogs or polynucleotide analogs biosynthesized from heterologous systems, and proteins and / or mRNA encoded by such nucleic acids.
[0083] As used herein, the term "fusion protein" refers to a protein containing two or more amino acid sequences that do not coexist in naturally occurring proteins. Fusion proteins can contain two or more amino acid sequences from the same or different organisms. The two or more amino acid sequences of a fusion protein are typically in-frame, without a stop codon between them, and are usually translated from mRNA as part of the fusion protein.
[0084] When referring to proteins according to (3), the terms “fusion protein” and “recombinant protein” are used interchangeably in this document.
[0085] As used herein, the terms "antibody" and "immunoglobulin" have the same meaning and are used interchangeably throughout this invention. As used herein, the term "antibody" refers to an immunoglobulin molecule and the immunologically active portion of an immunoglobulin molecule, i.e., a molecule containing an antigen-binding site that specifically binds to an antigen. Therefore, the term antibody encompasses not only the complete antibody molecule but also antibody fragments or derivatives.
[0086] In natural antibodies, two heavy chains are linked together by disulfide bonds, and each heavy chain is connected to a light chain via a disulfide bond. There are two types of light chains: λ (lambda) and κ (kappa). There are five main heavy chain classes (or isotypes) that determine the functional activity of the antibody molecule: IgM, IgD, IgG, IgA, and IgE. Each chain contains different sequence domains. The light chain includes two domains: a variable domain (VL) and a constant domain (CL). The heavy chain includes four domains: one variable domain (VH) and three constant domains (CH1, CH2, and CH3, collectively referred to as CH). Both the light chain variable region (VL) and the heavy chain variable region (VH) determine the binding recognition and specificity to the antigen. The light chain constant domain (CL) and the heavy chain constant domain (CH) confer important biological properties, such as antibody chain association, secretion, transplacental movement, complement binding, and binding to the Fc receptor (FcR). The Fv fragment is the N-terminal portion of the immunoglobulin Fab fragment and consists of a light chain and a variable portion of a heavy chain. Antibody specificity lies in the structural complementarity between the antibody binding site and the antigenic determinant. The antibody binding site is primarily composed of residues from the hypervariable region or complementarity-determining region (CDR). Sometimes, residues from the non-hypervariable region or frame region (FR) can affect the overall domain structure and thus the binding site. The complementarity-determining region or CDR is an amino acid sequence that collectively defines the binding affinity and specificity of the native Fv region, the natural immunoglobulin binding site. Both the light and heavy chains of immunoglobulins have three CDRs, named L-CDR1, L-CDR2, L-CDR3 and H-CDR1, H-CDR2, H-CDR3, respectively. Therefore, the antigen-binding site typically includes six CDRs, comprising CDR sets from both the heavy chain V region and the light chain V region. The frame region (FR) refers to the amino acid sequences interspersed between CDRs.
[0087] CDRs can be identified according to the definitions of Kabat and Chothia, the sum of the Kabat and Chothia definitions, AbM, contact, IMGT unique number and / or conformational definition, or any CDR identification method known in the art. Antibody CDRs can be identified as hypervariable regions originally defined by Kabat et al. See, for example, Kabat et al., 1992, Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, NIH, Washington DC. The location of CDRs can also be identified as structural loop structures originally described by Chothia et al. (see, for example, Chothia et al., Nature 342:877-883, 1989). Other methods for identifying CDRs include the “AbM definition,” a compromise between Kabat and Chothia derived using Oxford Molecular’s AbM antibody modeling software (now Accelrys0); the “contact definition,” based on observed antigen contact, described in MacCallum et al., J. Mol. Biol., 262:732-745, 1996; or the “IMGT unique number,” which relies on the high conservation of the variable region structure (see Lefranc, M.-P. Nucl. Acids Res., 33, D593-D597, 2005). In another method, referred to herein as the “conformation definition” of CDRs, the position of the CDR can be identified as the residue that contributes enthalpy to antigen binding. See, for example, Makabe et al., Journal of Biological Chemistry, 283:1156-1166, 2008. Other CDR boundary definitions may not strictly follow any of the methods described above, but will still overlap with at least a portion of the Kabat CDR, although they may be shortened or lengthened given that a particular residue or group of residues or even the entire CDR does not significantly affect the prediction or experimental results of antigen binding. As used herein, CDR may refer to a CDR defined by any method known in the art, including combinations of methods. The methods used herein may utilize a CDR defined according to any of these methods. For any given embodiment containing more than one CDR, unless otherwise specified, the CDR may be defined according to any of the Kabat, Chothia, extended, AbM, contact, IMGT unique number, and / or conformational definitions.
[0088] Exemplary databases of antibody sequences are described on the Abysis website www.bioinf.org.uk / abs (maintained by AC Martin in the Department of Biochemistry & Molecular Biology UniversityCollege London, London, England) and the VBASE2 website www.vbase2.org, which are accessible through them, as described in Retter et al., Nucl. Acids Res., 33 (Database issue): D671-D674 (2005). Sequences are preferably analyzed using the Abysis database, which integrates sequence data from Kabat, IMGT, and the Protein Data Bank (PDB) with structural data from the PDB. Unless otherwise stated, all CDRs listed herein are derived from the Abysis database website according to the illustrated scheme.
[0089] As used herein, the term "antibody" includes isolated antibodies, polyclonal antibodies, monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies (fully or partially humanized), animal antibodies, recombinant antibodies, chimeric antibodies, and antibody fragments.
[0090] As used herein, the term "monoclonal antibody" or "mAb" refers to an antibody composition having a homogeneous group of antibodies that bind to the same epitopes. This term is not limited to the type or source of the antibody, nor is it intended to be limited by its preparation method. Therefore, the term encompasses antibodies obtained from mouse hybridomas, as well as human monoclonal antibodies obtained using human rather than mouse hybridomas. The term also encompasses antibodies obtained by other methods known in the art for producing monoclonal antibodies, such as establishing eukaryotic cell lines through transient or stable transfection.
[0091] As used herein, the term "recombinant antibody" refers to an antibody expressed in cells or cell lines transfected with one or more expression vectors containing antibody-coding sequences that are not natively associated with the cells. Recombinant antibodies or fragments thereof are prepared, expressed, generated, or isolated by any recombinant method known to those skilled in the art.
[0092] In some implementations, when a “recombinant antibody” originates from a population of homogeneous antibodies that bind to the same epitope, it may also be a “monoclonal antibody.”
[0093] Therefore, the term "antibody fragment" as used herein includes, but is not limited to, variable fragments (Fv), single-chain Fv (scFv), bispecific antibodies (sc(Fv)2), single-chain antibodies, single-domain antibodies, Fab fragments, F(ab')2 fragments, Fab' fragments, disulfide-linked Fv (dsFv), chemically conjugated Fv (ccFv), biantibodies, and anti-idiotypic (anti-Id) antibodies, as well as any of the above-mentioned functional epitope-binding fragments. In some embodiments, antibodies also include affinities, nanobodies, and monoclonal antibodies. In some embodiments, specific antibodies include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, i.e., molecules containing antigen-binding sites. Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgAi, and IgA2), or subclass.
[0094] As used herein, the term "antigen-binding fragment (Fab)" refers to an antibody fragment containing a constant domain and a variable domain, one for each of the heavy and light chains. The variable domain contains the antigen-binding site. Typically, an antibody comprises a crystallizable region (Fc) and two antigen-binding fragments (Fab). The Fab fragments can be separated from the Fc, resulting in two Fab fragments, also known as F(ab')2 fragments or dimer antigen-binding fragments.
[0095] The term "isolated" refers to a protein (e.g., antibody) or nucleic acid that is substantially free of other cellular material and / or chemicals. For example, isolated antibodies are expressed by cells from a different species (e.g., human antibodies expressed in mouse cells) and are substantially free of other proteins from a different species. Protein purification techniques well known in the art can be used to isolate proteins that are substantially free of naturally occurring related components (or components associated with the cellular expression system used to produce the antibody).
[0096] As used herein, the term "antigen" refers to a biomolecule that specifically binds to a corresponding antibody. Antibodies from different repertoires bind to specific antigenic structures through interactions of their variable regions.
[0097] As used herein, the term "epitope" refers to the antigenic moiety to which an antibody specifically binds. Therefore, the term "epitope" includes any protein determinant capable of specifically binding to immunoglobulins or T-cell receptors.
[0098] A peptide is "immunoreactive" to an antibody when the antibody binds to it because the antibody recognizes a specific epitope contained in the peptide. Immunoreactivity can be determined by antibody binding, more specifically by antibody binding kinetics, and / or by binding competition using a known peptide containing the epitope targeted by the antibody as a competing agent. Techniques for determining whether a peptide is immunoreactive to an antibody are known in the art.
[0099] As used herein, the term "sample" means any biological material obtained from a subject or patient. In one respect, a sample may comprise blood, peritoneal fluid, CSF, saliva, or urine. In other respects, a sample may comprise whole blood, plasma, serum, B cells enriched from a blood sample, and cultured cells (e.g., B cells from a subject). A sample may also include biopsy or tissue samples, including neural tissue. In still other respects, a sample may comprise whole cells and / or cell lysates.
[0100] Samples can be processed to physically or mechanically disrupt tissue or cellular structures, thereby releasing intracellular components into a solution that may also contain enzymes, buffers, salts, detergents, etc., used to prepare biological samples for analysis using standard methods. Samples may also include processed samples, such as those obtained by passing the sample through or through a filtration device, after centrifugation, or by adhering to a medium, matrix, or support.
[0101] The terms "patient" or "individual" are used interchangeably herein and refer to a mammalian subject to diagnosis or treatment, preferably a human patient. In some cases, the methods of the present invention can be used in laboratory animals, veterinary applications, and the development of animal models of disease, including but not limited to rodents, including mice, rats, and hamsters; and primates.
[0102] The term "vector" refers to a nucleic acid that can be used to introduce another nucleic acid, which it is linked to, into a cell. One type of vector is the "plasmid," which is a linear or circular double-stranded DNA molecule that can be linked to an additional nucleic acid segment. Another type of vector is the viral vector (e.g., replication-defective retroviruses, adenoviruses, and adeno-associated viruses), which can introduce an additional DNA segment into the viral genome. Some vectors can replicate autonomously in the host cells in which they are introduced (e.g., bacterial vectors containing bacterial origins of replication and attachable mammalian vectors). Other vectors (e.g., non-attached mammalian vectors) integrate into the host cell's genome after introduction and thereby replicate along with the host genome.
[0103] "Expression vector" is a type of vector that can direct the expression of a selected polynucleotide. "Expression cell" is a cell that contains an expression vector.
[0104] If a regulatory sequence affects the expression of a nucleotide sequence (e.g., the level, timing, or location of expression), then the nucleotide sequence is "operably linked" to the regulatory sequence. A "regulatory sequence" is a nucleic acid that affects the expression (e.g., the level, timing, or location) of the nucleic acid to which it is operably linked. For example, a regulatory sequence may act on the regulated nucleic acid directly or via the action of one or more other molecules (e.g., polypeptides that bind to the regulatory sequence and / or the nucleic acid). Examples of regulatory sequences include promoters, enhancers, and other expression control elements.
[0105] As used herein, the terms "diagnostic" or "diagnosed" refer to the identification of a pathological condition or the presence or nature of a patient susceptible to the disease. Diagnostic methods vary in sensitivity and specificity. The "sensitivity" of a diagnostic test is the percentage of diseased individuals who test positive (the percentage of "true positives"). Diseased individuals not detected by the test are called "false negatives." Subjects who are not diseased and test negative in the test are called "true negatives." The "specificity" of a diagnostic test is 1 minus the false positive rate, where the "false positive" rate is defined as the proportion of patients who test positive but do not have the disease. Although a particular diagnostic method may not provide a definitive diagnosis of the condition, it is sufficient if the method provides a positive indication that aids in diagnosis.
[0106] As used in this article, the term “binding affinity” refers to the strength of the interaction between an antigen epitope and an antibody antigen-binding site.
[0107] This invention relates to novel antibodies specifically for the detection of human immunodeficiency virus 1 (HIV-1) p24 protein. These antibodies recognize novel and non-cross-reactive epitopes of the HIV-1 p24 protein and exhibit higher affinity and sensitivity compared to other commercially available products. Therefore, the antibodies described herein can be used as diagnostic reagents, standards, or positive controls in immunoassays for early HIV-1 detection. They can be used to detect any of the three major HIV-1 groups (M group (major), N group (novel), and O group (outlier)).
[0108] The present invention also relates to compositions and kits for detecting the presence of HIV-1 in samples, the compositions and kits comprising the anti-HIV-1 antibody.
[0109] I. Anti-HIV-1 antibody As used herein, in the context of two or more nucleic acid or polypeptide sequences, the terms "homology," "similarity," or "identity" refer to two or more sequences or subsequences that are identical or have a specific percentage of identical nucleotide or amino acid residues when compared and aligned to obtain maximum correspondence. To determine the homology / identity percentage, sequences are aligned for optimal comparison purposes (e.g., vacancies may be introduced into the sequence of the first amino acid or nucleic acid sequence to achieve optimal alignment with the second amino acid or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at that position. The percentage of identity between two sequences is a function of the number of identical positions shared by the sequences (i.e., identity % = number of identical positions # / total number of positions # (e.g., overlapping positions) x 100). In some embodiments, the two sequences being compared have the same length after vacancies are introduced within the sequences, where appropriate (e.g., excluding additional sequences extending beyond the compared sequences). For sequence comparisons between two sequences, the "corresponding" CDR refers to the CDR at the same position in the two sequences (e.g., CDR-H1 of each sequence).
[0110] Mathematical algorithms can be used to determine the percentage of identity, similarity, or homology between two sequences. A preferred, non-limiting example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and Altschul, 1990, Proc.Natl.Acad.Sci.USA, modified from Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. USA 90:5873-5877, and published in Proc.Natl.Acad.Sci. USA 87:2264-2268. Such an algorithm is incorporated into the NBLAST and XBLAST procedures of Altschul et al., 1990, J.Mol. Biol. 215:403-410. BLAST nucleotide searching can be performed using the NBLAST procedure, score = 100, word length = 12, to obtain nucleotide sequences homologous to nucleic acids encoding the protein of interest. BLAST protein search can be performed using the XBLAST program with a score of 50 and a word length of 3 to obtain amino acid sequences homologous to the protein of interest. For vacancy alignments used for comparison purposes, vacancy BLAST (as described in Altschul et al., 1997, Nucleic Acids Res. 25:3389-3402) can be used. When using BLAST and vacancy BLAST programs, the default parameters of each program (e.g., XBLAST and NBLAST) can be used. Another preferred, non-limiting example of a mathematical algorithm for sequence comparison is the algorithm of Myers and Miller, CABIOS (1989). Such an algorithm is incorporated into the ALIGN program (version 2.0), which is part of the GCG sequence alignment software package. When using the ALIGN program to compare amino acid sequences, a PAM120 weighted residue table, a vacancy length penalty of 12, and a vacancy penalty of 4 can be used.
[0111] In one embodiment described herein, the recombinant antibody comprises a light chain and a heavy chain. In other embodiments described herein, the recombinant antibody comprises two light chains and two heavy chains. The light chain of the recombinant antibody of the present invention may comprise two domains, namely a variable domain (VL) and a constant domain (CL). The heavy chain of the recombinant antibody of the present invention may comprise four domains, namely a variable domain (VH) and three constant domains (CH1, CH2, and CH3, collectively referred to as CH).
[0112] In some embodiments, the anti-HIV-1 antibody of the present invention is a monoclonal antibody. In other embodiments, the anti-HIV-1 antibody of the present invention is a recombinant antibody. In other embodiments, the anti-HIV-1 antibody is a recombinant monoclonal antibody as defined according to the present invention. In other embodiments, the anti-HIV-1 antibody is an isolated antibody.
[0113] In some embodiments, the anti-HIV-1 antibody is an antibody fragment. In a preferred embodiment, the antibody fragment is selected from variable fragments (Fv), single-chain Fv (scFv), bispecific antibodies (sc(Fv)2), single-chain antibodies, single-domain antibodies, Fab fragments, F(ab')2 fragments, Fab' fragments, disulfide-linked Fv (dsFv), chemically conjugated Fv (ccFv), biantibodies, anti-idiotype (anti-Id) antibodies, affinity molecules, nanobodies, and monoantibodies.
[0114] In one embodiment described herein, the anti-HIV-1 antibody comprises an Fc region and two Fab fragments. In other embodiments described herein, the anti-HIV-1 antibody is an antigen-binding fragment and does not contain an Fc region. In other embodiments described herein, the anti-HIV-1 antibody consists of one Fab fragment. In other embodiments described herein, the anti-HIV-1 antibody consists of two Fab fragments (F(ab)2).
[0115] In one embodiment described herein, the anti-HIV-1 antibody may be any type known to a person skilled in the art (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), or any class known to a person skilled in the art (e.g., IgG1, IgG2, IgG3, IgG4, IgAi, and IgA2) or any known subclass.
[0116] In one embodiment described herein, the anti-HIV-1 antibody is of the IgG type. In a preferred embodiment, the anti-HIV-1 antibody is of the IgG1, IgG2, IgG3, or IgG4 class. In another preferred embodiment, the anti-HIV-1 antibody is of the IgG1 or IgG2 class. In yet another preferred embodiment, the anti-HIV-1 antibody is of the IgG2a class.
[0117] Although the species of the antibodies of the present invention are not particularly limited, the species of the constant region of the antibodies of the present invention can be human, mouse, rabbit, rat, hamster, guinea pig, goat, sheep, horse, chicken, or any chimera of said species. In some preferred embodiments, the anti-HIV-1 antibody of the present invention comprises a constant region of mouse IgG1 class or mouse IgG2a class.
[0118] A. Light chain In some embodiments described herein, the anti-HIV-1 antibody comprises a light chain containing a complementarity-determining region (CDR). The CDR corresponds to a sequence identified by any CDR definition method known to a person skilled in the art. In some preferred embodiments, the CDR region corresponds to a sequence identified according to the Kabat numbering scheme. In other preferred embodiments, the CDR region may correspond to a sequence identified according to other numbering methods or a combination of Kabat and other numbering methods. For example, the CDR region may correspond to a sequence identified according to the Chothia numbering scheme.
[0119] In some embodiments described herein, the anti-HIV-1 antibody comprises a light chain including complementarity-determining regions L-CDR1, L-CDR2, and L-CDR3, each comprising a sequence of at least five consecutive amino acids selected from the following amino acid sequences: SEQ ID NO: 7, or SEQ ID NO: 8, or SEQ ID NO: 9. In some preferred embodiments, the sequence of L-CDR1 is selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 18, and SEQ ID NO: 21. In some preferred embodiments, the sequence of L-CDR2 is selected from the group consisting of: SEQ ID NO: 16, SEQ ID NO: 19, and SEQ ID NO: 22. In some preferred embodiments, the sequence of L-CDR3 is selected from the group consisting of: SEQ ID NO: 17, SEQ ID NO: 20, and SEQ ID NO: 23. In other preferred embodiments, the sequence of L-CDR1 is selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 18 and SEQ ID NO: 21, the sequence of L-CDR2 is selected from the group consisting of: SEQ ID NO: 16, SEQ ID NO: 19 and SEQ ID NO: 22, and the sequence of L-CDR3 is selected from the group consisting of: SEQ ID NO: 17, SEQ ID NO: 20 and SEQ ID NO: 23.
[0120] In another embodiment described herein, the variable region of the light chain of the anti-HIV-1 antibody of the present invention comprises the following amino acid sequence: SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9. In yet another embodiment, the variable region of the light chain of the recombinant antibody may have about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater homology with the following amino acid sequence: SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9. In some preferred embodiments, the light chain of the anti-HIV-1 antibody of the present invention comprises a sequence having about 90% homology with the following amino acid sequence: SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9.
[0121] In another embodiment described herein, the recombinant antibody comprises a light chain containing the following amino acid sequence: SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In other embodiments, the light chain of the recombinant antibody may have about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater homology with the following amino acid sequence: SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In some preferred embodiments, the light chain of the anti-HIV-1 antibody of the present invention comprises a sequence having about 90% homology with the following amino acid sequence: SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
[0122] B. Heavy chain In some embodiments described herein, the anti-HIV-1 antibody comprises a heavy chain containing a complementarity-determining region (CDR). The CDR corresponds to a sequence identified by any CDR definition method known to a person skilled in the art. In some preferred embodiments, the CDR region corresponds to a sequence identified according to the Kabat numbering scheme. In other preferred embodiments, the CDR region may correspond to a sequence identified according to other numbering methods or a combination of Kabat and other numbering methods. For example, the CDR region may correspond to a sequence identified according to the Chothia numbering scheme.
[0123] In some embodiments described herein, the anti-HIV-1 antibody comprises a heavy chain including complementarity-determining regions H-CDR1, H-CDR2, and H-CDR3, each comprising a sequence of at least five consecutive amino acids selected from the following amino acid sequences: SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12. In some preferred embodiments, the sequence of H-CDR1 is selected from the group consisting of: SEQ ID NO: 24, SEQ ID NO: 27, and SEQ ID NO: 30. In some preferred embodiments, the sequence of H-CDR2 is selected from the group consisting of: SEQ ID NO: 25, SEQ ID NO: 28, and SEQ ID NO: 31. In some preferred embodiments, the sequence of H-CDR3 is selected from the group consisting of: SEQ ID NO: 26, SEQ ID NO: 29, and SEQ ID NO: 32. In some preferred embodiments, the sequence of H-CDR1 is selected from the group consisting of: SEQ ID NO: 24, SEQ ID NO: 27 and SEQ ID NO: 30; the sequence of H-CDR2 is selected from the group consisting of: SEQ ID NO: 25, SEQ ID NO: 28 and SEQ ID NO: 31; and the sequence of H-CDR3 is selected from the group consisting of: SEQ ID NO: 26, SEQ ID NO: 29 and SEQ ID NO: 32.
[0124] In another embodiment described herein, the variable region of the heavy chain of the anti-HIV-1 antibody of the present invention comprises the following amino acid sequence: SEQ ID NO: 10 or SEQ ID NO: 11 or SEQ ID NO: 12. In yet another embodiment, the variable region of the heavy chain of the recombinant antibody may have about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater homology with the following amino acid sequence: SEQ ID NO: 10 or SEQ ID NO: 11 or SEQ ID NO: 12. In some preferred embodiments, the heavy chain of the anti-HIV-1 antibody of the present invention comprises a sequence having about 90% homology with the following amino acid sequence: SEQ ID NO: 10 or SEQ ID NO: 11 or SEQ ID NO: 12.
[0125] In another embodiment described herein, the recombinant antibody comprises a heavy chain containing the following amino acid sequence: SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6. In other embodiments, the light chain of the recombinant antibody may have about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater homology with the following amino acid sequence: SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6. In some preferred embodiments, the heavy chain of the anti-HIV-1 antibody of the present invention comprises a sequence having about 90% homology with the following amino acid sequence: SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6.
[0126] C. Exemplary anti-HIV-1 antibody In one embodiment described herein, the anti-HIV-1 antibody comprises a light chain including complementarity-determining regions L-CDR1, L-CDR2, and L-CDR3, wherein the amino acid sequence of L-CDR1 is SEQ ID NO: 15, the amino acid sequence of L-CDR2 is SEQ ID NO: 16, and the amino acid sequence of L-CDR3 is SEQ ID NO: 17.
[0127] In other embodiments described herein, the anti-HIV-1 antibody comprises a light chain including complementarity-determining regions L-CDR1, L-CDR2, and L-CDR3, wherein the amino acid sequence of L-CDR1 is SEQ ID NO: 18, the amino acid sequence of L-CDR2 is SEQ ID NO: 19, and the amino acid sequence of L-CDR3 is SEQ ID NO: 20.
[0128] In other embodiments described herein, the anti-HIV-1 antibody comprises a light chain including complementarity-determining regions L-CDR1, L-CDR2, and L-CDR3, wherein the amino acid sequence of L-CDR1 is SEQ ID NO: 21, the amino acid sequence of L-CDR2 is SEQ ID NO: 22, and the amino acid sequence of L-CDR3 is SEQ ID NO: 23.
[0129] In one embodiment described herein, the anti-HIV-1 antibody comprises a heavy chain including complementarity-determining regions H-CDR1, H-CDR2, and H-CDR3, wherein the amino acid sequence of H-CDR1 is SEQ ID NO: 24, the amino acid sequence of H-CDR2 is SEQ ID NO: 25, and the amino acid sequence of H-CDR3 is SEQ ID NO: 26.
[0130] In other embodiments described herein, the anti-HIV-1 antibody comprises a heavy chain including complementarity-determining regions H-CDR1, H-CDR2, and H-CDR3, wherein the amino acid sequence of H-CDR1 is SEQ ID NO: 27, the amino acid sequence of H-CDR2 is SEQ ID NO: 28, and the amino acid sequence of H-CDR3 is SEQ ID NO: 29.
[0131] In other embodiments described herein, the anti-HIV-1 antibody comprises a heavy chain including complementarity-determining regions H-CDR1, H-CDR2, and H-CDR3, wherein the amino acid sequence of H-CDR1 is SEQ ID NO: 30, the amino acid sequence of H-CDR2 is SEQ ID NO: 31, and the amino acid sequence of H-CDR3 is SEQ ID NO: 32.
[0132] The anti-HIV-1 antibody of the present invention may comprise any combination of the CDR regions of both the light chain and the heavy chain as described herein.
[0133] In a preferred embodiment described herein, the anti-HIV-1 antibody comprises a light chain including complementarity-determining regions L-CDR1, L-CDR2, and L-CDR3, wherein the amino acid sequence of L-CDR1 is SEQ ID NO: 15, the amino acid sequence of L-CDR2 is SEQ ID NO: 16, and the amino acid sequence of L-CDR3 is SEQ ID NO: 17; and a heavy chain including complementarity-determining regions H-CDR1, H-CDR2, and H-CDR3, wherein the amino acid sequence of H-CDR1 is SEQ ID NO: 24, the amino acid sequence of H-CDR2 is SEQ ID NO: 25, and the amino acid sequence of H-CDR3 is SEQ ID NO: 26.
[0134] In a preferred embodiment described herein, the anti-HIV-1 antibody comprises a light chain containing complementarity-determining regions L-CDR1, L-CDR2, and L-CDR3, wherein the amino acid sequence of L-CDR1 is SEQ ID NO: 15, the amino acid sequence of L-CDR2 is SEQ ID NO: 16, and the amino acid sequence of L-CDR3 is SEQ ID NO: 17; and a heavy chain containing complementarity-determining regions H-CDR1, H-CDR2, and H-CDR3, wherein the amino acid sequence of H-CDR1 is SEQ ID NO: 27, the amino acid sequence of H-CDR2 is SEQ ID NO: 28, and the amino acid sequence of H-CDR3 is SEQ ID NO: 29.
[0135] In a preferred embodiment described herein, the anti-HIV-1 antibody comprises a light chain including complementarity-determining regions L-CDR1, L-CDR2, and L-CDR3, wherein the amino acid sequence of L-CDR1 is SEQ ID NO: 15, the amino acid sequence of L-CDR2 is SEQ ID NO: 16, and the amino acid sequence of L-CDR3 is SEQ ID NO: 17; and a heavy chain including complementarity-determining regions H-CDR1, H-CDR2, and H-CDR3, wherein the amino acid sequence of H-CDR1 is SEQ ID NO: 30, the amino acid sequence of H-CDR2 is SEQ ID NO: 31, and the amino acid sequence of H-CDR3 is SEQ ID NO: 32.
[0136] In a preferred embodiment described herein, the anti-HIV-1 antibody comprises a light chain containing complementarity-determining regions L-CDR1, L-CDR2, and L-CDR3, wherein the amino acid sequence of L-CDR1 is SEQ ID NO: 18, the amino acid sequence of L-CDR2 is SEQ ID NO: 19, and the amino acid sequence of L-CDR3 is SEQ ID NO: 20; and a heavy chain containing complementarity-determining regions H-CDR1, H-CDR2, and H-CDR3, wherein the amino acid sequence of H-CDR1 is SEQ ID NO: 24, the amino acid sequence of H-CDR2 is SEQ ID NO: 25, and the amino acid sequence of H-CDR3 is SEQ ID NO: 26.
[0137] In a preferred embodiment described herein, the anti-HIV-1 antibody comprises a light chain including complementarity-determining regions L-CDR1, L-CDR2, and L-CDR3, wherein the amino acid sequence of L-CDR1 is SEQ ID NO: 18, the amino acid sequence of L-CDR2 is SEQ ID NO: 19, and the amino acid sequence of L-CDR3 is SEQ ID NO: 20; and a heavy chain including complementarity-determining regions H-CDR1, H-CDR2, and H-CDR3, wherein the amino acid sequence of H-CDR1 is SEQ ID NO: 27, the amino acid sequence of H-CDR2 is SEQ ID NO: 28, and the amino acid sequence of H-CDR3 is SEQ ID NO: 29.
[0138] In a preferred embodiment described herein, the anti-HIV-1 antibody comprises a light chain containing complementarity-determining regions L-CDR1, L-CDR2, and L-CDR3, wherein the amino acid sequence of L-CDR1 is SEQ ID NO: 18, the amino acid sequence of L-CDR2 is SEQ ID NO: 19, and the amino acid sequence of L-CDR3 is SEQ ID NO: 20; and a heavy chain containing complementarity-determining regions H-CDR1, H-CDR2, and H-CDR3, wherein the amino acid sequence of H-CDR1 is SEQ ID NO: 30, the amino acid sequence of H-CDR2 is SEQ ID NO: 31, and the amino acid sequence of H-CDR3 is SEQ ID NO: 32.
[0139] In a preferred embodiment described herein, the anti-HIV-1 antibody comprises a light chain containing complementarity-determining regions L-CDR1, L-CDR2, and L-CDR3, wherein the amino acid sequence of L-CDR1 is SEQ ID NO: 21, the amino acid sequence of L-CDR2 is SEQ ID NO: 22, and the amino acid sequence of L-CDR3 is SEQ ID NO: 23; and a heavy chain containing complementarity-determining regions H-CDR1, H-CDR2, and H-CDR3, wherein the amino acid sequence of H-CDR1 is SEQ ID NO: 24, the amino acid sequence of H-CDR2 is SEQ ID NO: 25, and the amino acid sequence of H-CDR3 is SEQ ID NO: 26.
[0140] In a preferred embodiment described herein, the anti-HIV-1 antibody comprises a light chain including complementarity-determining regions L-CDR1, L-CDR2, and L-CDR3, wherein the amino acid sequence of L-CDR1 is SEQ ID NO: 21, the amino acid sequence of L-CDR2 is SEQ ID NO: 22, and the amino acid sequence of L-CDR3 is SEQ ID NO: 23; and a heavy chain including complementarity-determining regions H-CDR1, H-CDR2, and H-CDR3, wherein the amino acid sequence of H-CDR1 is SEQ ID NO: 27, the amino acid sequence of H-CDR2 is SEQ ID NO: 28, and the amino acid sequence of H-CDR3 is SEQ ID NO: 29.
[0141] In a preferred embodiment described herein, the anti-HIV-1 antibody comprises a light chain containing complementarity-determining regions L-CDR1, L-CDR2, and L-CDR3, wherein the amino acid sequence of L-CDR1 is SEQ ID NO: 21, the amino acid sequence of L-CDR2 is SEQ ID NO: 22, and the amino acid sequence of L-CDR3 is SEQ ID NO: 23; and a heavy chain containing complementarity-determining regions H-CDR1, H-CDR2, and H-CDR3, wherein the amino acid sequence of H-CDR1 is SEQ ID NO: 30, the amino acid sequence of H-CDR2 is SEQ ID NO: 31, and the amino acid sequence of H-CDR3 is SEQ ID NO: 32.
[0142] In one embodiment described herein, the anti-HIV-1 antibody comprises a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9; and a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12.
[0143] In a preferred embodiment, the anti-HIV-1 antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 7 and a heavy chain containing the amino acid sequence of SEQ ID NO: 10.
[0144] In a preferred embodiment, the anti-HIV-1 antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 7 and a heavy chain containing the amino acid sequence of SEQ ID NO: 11.
[0145] In a preferred embodiment, the anti-HIV-1 antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 7 and a heavy chain containing the amino acid sequence of SEQ ID NO: 12.
[0146] In a preferred embodiment, the anti-HIV-1 antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 8 and a heavy chain containing the amino acid sequence of SEQ ID NO: 10.
[0147] In a preferred embodiment, the anti-HIV-1 antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 8 and a heavy chain containing the amino acid sequence of SEQ ID NO: 11.
[0148] In a preferred embodiment, the anti-HIV-1 antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 8 and a heavy chain containing the amino acid sequence of SEQ ID NO: 12.
[0149] In a preferred embodiment, the anti-HIV-1 antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 9 and a heavy chain containing the amino acid sequence of SEQ ID NO: 10.
[0150] In a preferred embodiment, the anti-HIV-1 antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 9 and a heavy chain containing the amino acid sequence of SEQ ID NO: 11.
[0151] In a preferred embodiment, the anti-HIV-1 antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 9 and a heavy chain containing the amino acid sequence of SEQ ID NO: 12.
[0152] In other preferred embodiments, the light chain of the anti-HIV-1 antibody may have about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater homology with the amino acid sequence consisting of: SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9, and the heavy chain of the anti-HIV-1 antibody may have about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater homology with the amino acid sequence consisting of: SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12.
[0153] In one embodiment described herein, the anti-HIV-1 antibody comprises a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; and a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6.
[0154] In a preferred embodiment, the anti-HIV-1 antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 1 and a heavy chain containing the amino acid sequence of SEQ ID NO: 4.
[0155] In a preferred embodiment, the anti-HIV-1 antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 1 and a heavy chain containing the amino acid sequence of SEQ ID NO: 5.
[0156] In a preferred embodiment, the anti-HIV-1 antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 1 and a heavy chain containing the amino acid sequence of SEQ ID NO: 6.
[0157] In a preferred embodiment, the anti-HIV-1 antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 2 and a heavy chain containing the amino acid sequence of SEQ ID NO: 4.
[0158] In a preferred embodiment, the anti-HIV-1 antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 2 and a heavy chain containing the amino acid sequence of SEQ ID NO: 5.
[0159] In a preferred embodiment, the anti-HIV-1 antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 2 and a heavy chain containing the amino acid sequence of SEQ ID NO: 6.
[0160] In a preferred embodiment, the anti-HIV-1 antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 3 and a heavy chain containing the amino acid sequence of SEQ ID NO: 4.
[0161] In a preferred embodiment, the anti-HIV-1 antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 3 and a heavy chain containing the amino acid sequence of SEQ ID NO: 5.
[0162] In a preferred embodiment, the anti-HIV-1 antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 3 and a heavy chain containing the amino acid sequence of SEQ ID NO: 6.
[0163] In other preferred embodiments, the light chain of the anti-HIV-1 antibody may have about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater homology with the amino acid sequence consisting of: SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, and the heavy chain of the anti-HIV-1 antibody may have about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater homology with the amino acid sequence consisting of: SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6.
[0164] In some preferred embodiments, the anti-HIV-1 antibody of the present invention specifically binds to the HIV-1 p24 protein. In some embodiments, the anti-HIV-1 antibody of the present invention binds to an epitope of the HIV-1 p24 protein. In some preferred embodiments, the anti-HIV-1 antibody of the present invention binds to a linear epitope of the HIV-1 p24 protein. In some preferred embodiments, the anti-HIV-1 antibody of the present invention binds to a linear epitope comprising at least five consecutive amino acids, said consecutive amino acids being selected from the amino acid sequence of the HIV-1 p24 protein (SEQ ID NO: 35) or a sequence having at least 90% homology with said sequence. In other embodiments, the amino acid sequence of the HIV-1 p24 protein is listed in SEQ ID NO: 36.
[0165] In other preferred embodiments, the anti-HIV-1 antibody of the present invention binds to an epitope of the HIV-1 p24 protein, characterized in that the epitope comprises the amino acid sequence of SEQ ID NO: 33.
[0166] In a more preferred embodiment, the anti-HIV-1 antibody of the present invention binds to an epitope of the HIV-1 p24 protein, characterized in that the epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 33, and wherein the antibody comprises a light chain, the light chain comprising complementarity-determining regions L-CDR1, L-CDR2, and L-CDR3, wherein the amino acid sequence of L-CDR1 is selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 18, and SEQ ID NO: 21, the amino acid sequence of L-CDR2 is selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 19, and SEQ ID NO: 22, and the amino acid sequence of L-CDR3 is selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 20, and SEQ ID NO: 23; and further comprises a heavy chain, the heavy chain comprising complementarity-determining regions H-CDR1, H-CDR2, and H-CDR3, wherein the amino acid sequence of H-CDR1 is selected from the group consisting of SEQ ID NO: 24. SEQ ID NO: 27 and SEQ ID NO: 30, the amino acid sequence of H-CDR2 is selected from the group consisting of: SEQ ID NO: 25, SEQ ID NO: 28 and SEQ ID NO: 31, and the amino acid sequence of H-CDR3 is selected from the group consisting of: SEQ ID NO: 26, SEQ ID NO: 29 and SEQ ID NO: 32.
[0167] In some preferred embodiments, the anti-HIV-1 antibody of the present invention binds to an epitope of the HIV-1 p24 protein, characterized in that the epitope comprises the amino acid sequence of SEQ ID NO: 33 and wherein the antibody comprises a light chain, the light chain comprising complementarity-determining regions L-CDR1, L-CDR2, and L-CDR3, wherein the amino acid sequence of L-CDR1 is SEQ ID NO: 18, the amino acid sequence of L-CDR2 is SEQ ID NO: 19, and the amino acid sequence of L-CDR3 is SEQ ID NO: 20; and the antibody further comprises a heavy chain, the heavy chain comprising complementarity-determining regions H-CDR1, H-CDR2, and H-CDR3, wherein the amino acid sequence of H-CDR1 is SEQ ID NO: 27, the amino acid sequence of H-CDR2 is SEQ ID NO: 28, and the amino acid sequence of H-CDR3 is SEQ ID NO: 29.
[0168] In some embodiments, the anti-HIV-1 antibody of the present invention is bound to a solid support.
[0169] D. Affinity Label The anti-HIV-1 antibody according to the present invention may optionally include an affinity tag. The affinity tag can be used for purification. Although the choice of affinity tag is not particularly limited, exemplary affinity tags include polyhistidine, glutathione S-transferase (GST), chitin-binding protein, maltose-binding protein (MBP), streptavidin-binding peptide (Strep tag), isopeptide bond formation, FLAG tag, V5 tag, Myc tag, HA tag, NE tag, AviTag, calcitonin tag, polyglutamic acid, S tag, SBP tag, Softag 1, Softag 3, TC tag, VSV tag, Xpress tag, Isopeptag, SpyTag, SnoopTag, biotinylate carboxyl carrier protein, green fluorescent protein tag, HaloTag, Nus tag, and thioredoxin tag. However, the anti-HIV-1 antibody may lack an affinity tag, for example, if the affinity tag is removed after use, or if a strategy that does not require an affinity tag is used to purify the antibody. An example affinity tag is polyhistidine, which typically contains an amino acid sequence with between 4 and 10 consecutive histidines.
[0170] The anti-HIV-1 antibody of the present invention may optionally include an affinity tag and may optionally be purified using said affinity tag. Several methods for purifying anti-HIV-1 antibodies are available in the prior art and are well known to those skilled in the art. Exemplary purification methods for anti-HIV-1 antibodies, with or without an affinity tag, include immobilized metal affinity chromatography (IMAC), protein A / G affinity chromatography, exchange chromatography (IEX or IEC), hydrophobic interaction chromatography (HIC), and / or other techniques besides IMAC or protein A / G that utilize tags and affinity chromatography. The purification methods and tags used should not be considered limiting.
[0171] II. Nucleic Acids, Cloned Cells, and Expression Cells This invention also relates to nucleic acids comprising a nucleotide sequence encoding an anti-HIV-1 antibody described herein. The nucleic acid may be an isolated nucleic acid. The nucleic acid may be DNA or RNA. The DNA comprising the nucleotide sequence encoding an anti-HIV-1 antibody described herein typically contains a promoter operatively linked to that nucleotide sequence. The promoter is preferably capable of driving constitutive or inducible expression of the nucleotide sequence in expression cells of interest. The nucleic acid may also contain selection markers that can be used to select cells containing said nucleic acid of interest. Available selection markers are well known to those skilled in the art. The exact nucleotide sequence of the nucleic acid is not particularly limited, as long as the nucleotide sequence encodes the anti-HIV-1 antibody described herein. For example, codons may be selected to match codon bias in expression cells of interest (e.g., mammalian cells, such as human cells) and / or for convenience in the cloning process. The DNA may be a plasmid, for example, which may contain an origin of replication (e.g., for plasmid replication in prokaryotic cells).
[0172] In one embodiment described herein, the nucleic acid comprises a nucleotide sequence encoding the anti-HIV-1 antibody of the present invention, a promoter operatively linked to the nucleotide sequence, and a selection marker.
[0173] In some preferred embodiments, the nucleic acid comprises a nucleotide sequence selected from the group consisting of: SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, and SEQ ID NO: 42. In a more preferred embodiment, the nucleic acid of the light chain of the anti-HIV-1 antibody of the present invention comprises a nucleotide sequence selected from the group consisting of: SEQ ID NO: 37, SEQ ID NO: 39, and SEQ ID NO: 41, and the nucleic acid of the heavy chain of the anti-HIV-1 antibody of the present invention comprises a nucleotide sequence selected from the group consisting of: SEQ ID NO: 38, SEQ ID NO: 40, and SEQ ID NO: 42.
[0174] In some embodiments, the light and heavy chain nucleic acids of the anti-HIV-1 antibody of the present invention comprise the nucleotide sequences of SEQ ID NO: 37 and SEQ ID NO: 38, respectively. In other embodiments, the light and heavy chain nucleic acids of the anti-HIV-1 antibody of the present invention comprise the nucleotide sequences of SEQ ID NO: 39 and SEQ ID NO: 40, respectively. In other embodiments, the light and heavy chain nucleic acids of the anti-HIV-1 antibody of the present invention comprise the nucleotide sequences of SEQ ID NO: 41 and SEQ ID NO: 42, respectively.
[0175] Various aspects of the invention also relate to a cell comprising nucleic acid containing a nucleotide sequence encoding an anti-HIV-1 antibody as described herein. The cell may be an expression cell or a cloned cell. Nucleic acid is typically cloned in *E. coli*, but other cloned cells may also be used.
[0176] If the cell is an expression cell, the nucleic acid may optionally be a chromosomal nucleic acid, meaning that its nucleotide sequence is integrated into the chromosome, although the nucleic acid may exist in the expression cell, for example, as extrachromosomal DNA or as a vector, such as a plasmid, granulosome, or bacteriophage. The form of the vector should not be considered restrictive.
[0177] In one embodiment described herein, the cells are typically expression cells. The nature of the expression cells is not particularly limited. Mammalian expression cells may allow for favorable folding, post-translational modification, and / or secretion of recombinant or oligomeric recombinant antibodies, although other eukaryotic or prokaryotic cells may be used as expression cells. Exemplary expression cells include CHO cell lines such as TunaCHO or ExpiCHO, Expi293, BHK, NSO, Sp2 / O, COS, C127, HEK, HT-1080, PER.C6, HeLa, and Jurkat cells. Cells may also be selected for vector integration, more preferably for plasmid DNA integration.
[0178] The anti-HIV-1 antibody of the present invention can be generated by a strategy of appropriately transfecting a nucleic acid containing a nucleotide sequence encoding an anti-HIV-1 antibody into mammalian cells. Those skilled in the art will know of various techniques (lipid transfection, electroporation, etc.) that can be used to transfect nucleic acids into selected cell lines. Therefore, the choice of mammalian cell lines and transfection strategies should not be considered limiting. Cell lines can be further selected to integrate plasmid DNA.
[0179] In a preferred embodiment described herein, the cells contain the anti-HIV-1 antibody of the present invention.
[0180] III. Compositions and Kits Various aspects of the present invention relate to compositions comprising anti-HIV-1 antibodies as described herein.
[0181] In one embodiment described herein, the composition comprises the anti-HIV-1 antibody of the present invention and a solid support.
[0182] In other embodiments, the composition comprises the anti-HIV-1 antibody of the present invention and a solid support, wherein the anti-HIV-1 antibody is covalently or non-covalently bound to the solid support. As used herein, the term "non-covalent binding" refers to a specific binding such as between an antibody and its antigen, a ligand and its receptor, or an enzyme and its substrate, exemplified by the interaction between a streptavidin-binding protein and streptavidin or between an antibody and its antigen.
[0183] In other embodiments, the composition comprises the anti-HIV-1 antibody of the present invention and a solid support, wherein the anti-HIV-1 antibody binds directly or indirectly to the solid support. As used herein, the term “direct” binding refers to the direct conjugation of a molecule to the solid support, such as the gold-thiol interaction of binding the cysteine thiol of the anti-HIV-1 antibody to a gold surface. As used herein, the term “indirect” binding includes the specific binding of the anti-HIV-1 antibody to another molecule directly bound to the solid support; for example, the anti-HIV-1 antibody may bind to an antibody directly bound to the solid support, thereby indirectly binding the anti-HIV-1 antibody to the solid support. The term “indirect” binding is not related to the number of molecules between the anti-HIV-1 antibody and the solid support, provided that (a) each interaction between the daisy chains of the molecules is a specific or covalent interaction, and (b) the terminal molecule of the daisy chain binds directly to the solid support.
[0184] Solid supports may include particles, beads, membranes, surfaces, peptide chips, microtiter plates, or the solid phase of a chromatographic column. Preferably, the solid support may be latex beads.
[0185] The composition may comprise a plurality of beads or particles, wherein each of the plurality of beads or particles is directly or indirectly bound to at least one anti-HIV-1 antibody as described herein. The composition may comprise a plurality of beads or particles, wherein each of the plurality of beads or particles is covalently or non-covalently bound to at least one anti-HIV-1 antibody as described herein.
[0186] Various aspects of the implementation scheme relate to a kit for detecting the presence of HIV-1 in a sample, the kit comprising at least one anti-HIV-1 antibody as described herein and a solid support or composition. In some embodiments, the at least one antibody is covalently or non-covalently bound to the solid support.
[0187] The anti-HIV-1 antibodies, compositions, and kits described herein can be used, for example, in assays to detect the presence of HIV-1 in a sample or to measure the concentration of HIV-1 in a sample, but they are not limited to said assays. The anti-HIV-1 antibodies, compositions, and kits of the present invention can also be used to detect HIV-1 alone or in combination with other antibodies used to detect other pathogens (such as multiplex assays and methods) to detect HIV-1.
[0188] In some preferred embodiments, the anti-HIV-1 antibody of the present invention is used in methods and assays for detecting other RNA viruses. In other embodiments, the anti-HIV-1 antibody and other anti-HIV-2 antibodies are used in methods and assays for simultaneously detecting HIV-1 and HIV-2 in a sample. In a more preferred embodiment, the anti-HIV-1 antibody and other anti-HIV-2 antibodies are used in methods and assays for specifically detecting HIV-1 p24 protein and HIV-2 p26 protein in a sample.
[0189] The scope of this invention also covers methods and assays for detecting HIV-1 in samples that use more than one anti-HIV-1 antibody as described herein.
[0190] The invention is described in more detail below by way of illustrative embodiments, but this does not constitute a limitation thereof.
[0191] illustration Example 1: Optimal anti-HIV antibody and stable cell line production The specific combinations of light and heavy chains of the present invention produce preferred antibodies, as disclosed herein: The variable and constant regions of each antibody were cloned into a bicistronic vector and expressed in Chinese hamster ovary (CHO) cells. The manufacturing characteristics of each antibody were evaluated based on its ability to generate stable cell line clones and the reproducible expression and purification of functional antibodies.
[0192] Pool Development Transfection: Three constructs containing the nucleotide sequences (SEQ ID NO: 37 to 42) of antibodies #A, #B, and #D were generated in bicistronic expression vectors containing the heavy and light chains of each antibody. To express the antibodies, CHO cells were electroporated with 200 µg of DNA to create stable cell lines. Twenty-four hours later, the transfected cells were counted and placed in selective medium to stabilize and integrate the protein genes.
[0193] Pool generation: Transfected cells were cultured at a density of 0.5 x 10⁻⁶. 6Cells were seeded at a density of [number] cells / mL into 250 mL shake flasks containing 50 mL working volume of selection medium and incubated at 37°C and 5% CO2. During the selection process, cells were spin-downed and resuspended in fresh selection medium every 2–3 days until the cells regained their growth rate and viability. Cell culture growth was monitored by viable cell density (VCD), percentage of viability, and titer.
[0194] Production Pool: A one-liter production run was conducted from the stabilization pool to evaluate VCD, titer, and viability. Cells were scaled up in production medium in 3 L shake flasks (1 L working volume). The conditioned medium supernatant harvested from each stabilization pool production run was clarified by centrifugation and the protein was purified by affinity purification using a Protein A column (Tables 2-4).
[0195] Cell line banking: growing cells to 2.5 x 10⁻⁶. 6 Cells / ml. Viability was above 95% at harvest for cell bank construction. Cells were then centrifuged, and the cell pellet was resuspended in CHO complete medium containing 7.5% dimethyl sulfoxide (DMSO) (Sigma-Aldrich, D1435) until a cell count of 15 x 10⁶ cells / ml was achieved per flask. 6 Each cell. Five vials were produced from each pool and frozen for preservation in liquid nitrogen. Stable antibody production Starting with the optimal pre-established cell lines for antibodies #A, #B, and #D, stable clones were obtained via single-cell cloning. The optimal clone for each antibody was selected based on the expression levels and bioanalytical characterization of purified materials from antibody #A, #B, and #D during production runs. Bioanalytical characterization included SE-UPLC and SDS-PAGE. Figures 1-3 ).
[0196] Example 2: Antibody Modeling and Evaluation Using the computational and modeling software Bioiluminate (Schrodinger), version 3.5, three-dimensional structural models of antibodies #A, #B, and #D were constructed based on antibody homology. In short, the amino acid sequences of the VH and VL regions of antibodies #A, #B, and #D were loaded into Bioiluminate. Frame regions and CDRs were identified by searching antibody structures in a protein database (PDB) and selecting PDB templates based on high sequence similarity and structure fitness (Table 5). The predicted CDR sequences for each antibody of this invention are shown in Table 5, and the PDB predicted structures of antibodies #A, #B, and #D are shown in Table 5. Figure 4 A, Figure 4 B and Figure 4 In D, for antibody #A, the PDB structural code 2XKN is used for homology lookup, while codes 5OPY and 1F3D are used for antibodies B# and #D, respectively.
[0197] Antibodies #A and #B are produced from the IgG1k isotype, while antibody #D is produced from the IgG2ak isotype. Analysis of the nucleotide sequences of the three antibodies showed that all generated heavy chains (VH) and light chains (VL) possessed unique complementarity-determining regions (CDRs) when queried using IgBLAST, an algorithm developed by the National Center for Biotechnology Information (NCBI) to facilitate queries against the ImMunoGeneTics Database (IMGT). Lefranc MP. Lefranc G. IMGT® and 30 years of Immunoinformatics Insight in Antibody V and C Domain Structure and Function. In Jefferis R; Strohl WR, Kato K. Antibodies 2019, vol. 8(29); 1-21 Analysis of the variable domain sequences of immunoglobulins.
[0198] Example 3: Epitope Plotting mAb D The HIV-p24 sequence was extended via neutral GGSGSGSG linkers at the C and N ends to avoid truncated peptides. The extended antigen sequence was translated into 15-amino acid linear peptides with 14-amino acid overlap between peptides. The resulting HIV-p24 peptide microarray contained 232 different linear peptides, printed in duplicate (464 dots), and framed with additional HA (YPYDVPDYAG, 38 dots) and c-Myc (EQKLISEEDL, 38 dots) control peptides.
[0199] Wash buffer: PBS, pH 7.4 containing 0.05% Tween 20; wash 3 x 10 seconds after each incubation step. Blocking buffer: Rockland Blocking Buffer MB-070 (30 min before the first assay) Incubation buffer: Wash buffer containing 10% blocking buffer Assay conditions: Antibody concentrations in incubation buffer were 1 µg / ml, 10 µg / ml, and 100 µg / ml; incubation was performed at 4°C for 16 h; and the mixture was shaken at 140 rpm. Secondary antibody: Goat anti-mouse IgG (H+L) DyLight680 (0.2 µg / ml); stained in incubation buffer at RT for 45 min. Control antibody: Mouse monoclonal anti-HA (12CA5) DyLight800 (0.5 µg / ml); stained in incubation buffer at RT for 45 min. Scanner: LI-COR Odyssey imaging system; scan offset 0.65 mm, resolution 21 µm, scan intensity 7 / 7 (red = 680 nm / green = 800 nm) Pre-staining of the HIV-p24 peptide microarray was performed using secondary goat anti-mouse IgG (H+L) DyLight680 antibody in incubation buffer to investigate background interactions with antigen-derived peptides that might interfere with the primary assay. Subsequently, other copies of the HIV-p24 peptide microarray were incubated with monoclonal antibody D at concentrations of 1 µg / ml, 10 µg / ml, and 100 µg / ml in incubation buffer, followed by staining with secondary and control antibodies and readout at a 7 / 7 (red / green) scan intensity. Additional HA peptides constituting the peptide microarray were then stained as internal quality controls to confirm assay quality and the integrity of the peptide microarray.
[0200] Epitope mapping of mAb D against HIV-p24, and subsequent epitope transposition scans, highlighted the conserved 7-amino acid core motif PIAPGQM (SEQ ID NO:33).
[0201] Example 4: Study on Epitope Binning Molecular docking and Western blot evaluation of antibodies #A, #B, and #D showed that these antibodies recognize linear epitopes in regions 1, 4, and 7 of the HIV-1 p24 protein, respectively. To further confirm these observations, tandem epitope binning was performed using a biolayer interferometer (BLI). A yeast-derived version of the HIV-1 p24 antigen was biotinylated (bt-p24) and loaded onto a streptavidin (SA) biosensor for 300 seconds. The loaded sensor was then immersed in a saturated antibody (100 µg / mL) for 600 seconds, followed by an immersion in a competitive antibody (25 µg / mL) for 300 seconds. Results showed that antibodies #B and #D increased the BLI signal response when antibody #A bound to HIV-1 p24, indicating that antibodies #B and #D bound to different epitopes compared to antibody A. Similarly, if antibody #A or #D was used as a saturating antibody, the other antibodies did not show competition for the same epitopes. Figures 9-10 ).
[0202] Table 6 summarizes the epitope binning data for antibodies #A, #B, and #D. In short, the BLI signals for both competitive and saturating antibodies were normalized against the buffer. A threshold for determining antibody blocking or binding was set to 0.02 to allow for online identification of self-blocking pairs (grey indicates binding, bold indicates self-blocking) on the diagonal of the matrix. The PEARSON correlation coefficient for antibody #A was calculated using the PEARSON function in Microsoft Excel. Liao-Chan S. et al., Monoclonal Antibody Binding-site Diversity Assessment with a Cell-based Clustering Assay.Journal of Immunological Methods 2014, vol. 405;1-14) Three different test chambers were used to identify antibodies #A, #B, and #D. No antibody blocking was observed. Example 5: Affinity assessment of anti-HIV-1 antibodies #A, #B and #D To investigate the interaction between antibodies #A, #B, and #D and the HIV-1 p24 antigen in more detail, affinity analysis was performed using BLI. Antibodies #A, #B, and #D were compared to a commercial monoclonal antibody (commercial mAb #1). Antibodies #A, #B, and #D, as well as commercial mAb #1, were captured using an anti-mouse Fc-specific coated biosensor tip (ForteBio). Concentration gradients for each antibody ranged from 0.1 nM to 33 nM, and each dilution was prepared in phosphate-buffered saline (PBS) containing 0.01% (w / v) bovine serum albumin (BSA) and 0.02% (v / v) detergent Tween-20. Recorded sensor maps were fitted using a 1:1 binding model, and the equilibrium constant KD was calculated as the ratio of dissociation rate to association rate (kd / ka). The antibodies tested were ranked based on the calculated affinity constants as follows: Antibody #B ~ Antibody #D > Antibody #A > Commercial mAb #1. Although the exact KD values for antibodies #B and #D could not be calculated due to the observed long dissociation curves, the data provided show that the calculated KD values for antibodies #A, #B, and #D are lower than those observed for commercial mAb #1 (Table 7). This data supports the observation that antibodies #A, #B, and #D exhibit higher affinity for HIV-1 p24 than commercial mAb #1. Example 6: Binding ability of anti-HIV-1 antibodies #A, #B and #D To further evaluate the binding of antibodies #A, #B, and #D to the HIV-1 p24 antigen, an indirect ELISA assay was performed. An initial concentration of 2 µg / mL was used, and serial 1:10 dilutions were performed until a concentration of 2 x 10⁻⁶ was achieved. -2 At low antibody concentrations of ng / mL, titration profiles were generated for each antibody. The performance of each antibody was compared with that of a commercial clone (commercial mAb #2). Figure 10 (Left). Data shows that antibodies #A, #B, and #D have higher signal-to-noise ratios (S / N) compared to commercial mAb #2, primarily at concentrations between 20 ng / mL and 2000 ng / mL, and these antibodies also exhibit lower EC50 values ( Figure 10 ,right).
[0203] in conclusion Functional assays were performed, comparing anti-HIV-1 antibodies #A, #B, and #D with commercial anti-HIV-1 p24 antibodies from commercial mAbs #1 and #2. Binding affinity and potency of each antibody were assessed by BLI and indirect ELISA. In both assays, HIV-1 antibodies #A, #B, and #D showed better affinity and better EC50 values compared to the tested commercial antibodies (see [link to kinetic analysis]). Figure 9 See Table 7, and for ELISA data, see [link to Table 7]. Figure 10 ).
[0204] The experimental data provided herein demonstrate that the anti-HIV-1 antibody of the present invention can be used to detect the HIV-1 structural p24 protein. Compared with similar products on the market, the antibody exhibits improved properties in terms of affinity, sensitivity, potency, expression, solubility, and manufacturability, and its use in serology can help shorten the time between HIV-1 infection and diagnostic events; thus preventing secondary viral transmission.
[0205] Concordance Table Unless otherwise stated, all CDR sequences are derived from Chothia using the Abysis database.
Claims
1. An anti-HIV-1 antibody comprising a light chain, said light chain comprising a complementarity-determining region (L-CDR1), a complementarity-determining region (L-CDR2), and a complementarity-determining region (L-CDR3), wherein... The amino acid sequence of L-CDR1 is selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21 and sequences differing from any one of SEQ ID NO: 15, 18 and 21 by one or two substitutions, deletions or additions. The amino acid sequence of L-CDR2 is selected from SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22 and the group consisting of sequences that differ from any one of SEQ ID NO: 16, 19 and 22 by one or two substitutions, deletions or additions. The amino acid sequence of L-CDR3 is selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23 and sequences that differ from any one of SEQ ID NO: 17, 20 and 23 by one or two substitutions, deletions or additions.
2. The anti-HIV-1 antibody according to claim 1, wherein the antibody comprises a heavy chain, the heavy chain comprising a complementarity-determining region H-CDR1, a complementarity-determining region H-CDR2, and a complementarity-determining region H-CDR3, wherein... The amino acid sequence of H-CDR1 is selected from the group consisting of SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30 and sequences differing from any one of SEQ ID NO: 24, 27 and 30 by one or two substitutions, deletions or additions. The amino acid sequence of H-CDR2 is selected from SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 31 and the group consisting of sequences differing from any one of SEQ ID NO: 25, 28 and 31 by one or two substitutions, deletions or additions, and The amino acid sequence of H-CDR3 is selected from the group consisting of SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32 and sequences that differ from any one of SEQ ID NO: 26, 29 and 32 by one or two substitutions, deletions or additions.
3. The anti-HIV-1 antibody according to any one of the preceding claims, wherein the light chain comprises a sequence having about 90% homology with the following amino acid sequences: SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO:
9.
4. The anti-HIV-1 antibody according to claim 3, wherein the light chain comprises the following amino acid sequence: SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO:
9.
5. The anti-HIV-1 antibody according to any one of the preceding claims, wherein the heavy chain comprises a sequence having about 90% homology with the following amino acid sequences: SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO:
12.
6. The anti-HIV-1 antibody according to claim 5, wherein the heavy chain comprises the following amino acid sequence: SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO:
12.
7. The anti-HIV-1 antibody according to any one of the preceding claims, wherein the amino acid sequence of L-CDR1 comprises SEQ ID NO: 15 or differs from SEQ ID NO: 15 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR2 contains SEQ ID NO: 16 or differs from SEQ ID NO: 16 by one or two substitutions, deletions, or additions, and The amino acid sequence of L-CDR3 contains SEQ ID NO: 17 or differs from SEQ ID NO: 17 by one or two substitutions, deletions, or additions.
8. The anti-HIV-1 antibody according to any one of claims 1 to 6, wherein the amino acid sequence of L-CDR1 comprises SEQ ID NO: 18 or differs from SEQ ID NO: 18 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR2 contains SEQ ID NO: 19 or differs from SEQ ID NO: 19 by one or two substitutions, deletions, or additions, and The amino acid sequence of L-CDR3 contains SEQ ID NO: 20 or differs from SEQ ID NO: 20 by one or two substitutions, deletions, or additions.
9. The anti-HIV-1 antibody according to any one of claims 1 to 6, wherein the amino acid sequence of L-CDR1 comprises SEQ ID NO: 21 or differs from SEQ ID NO: 21 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR2 contains SEQ ID NO: 22 or differs from SEQ ID NO: 22 by one or two substitutions, deletions, or additions, and The amino acid sequence of L-CDR3 contains SEQ ID NO: 23 or differs from SEQ ID NO: 23 by one or two substitutions, deletions, or additions.
10. The anti-HIV-1 antibody according to any one of claims 1 to 7, wherein the amino acid sequence of H-CDR1 comprises SEQ ID NO: 24 or a sequence differing from SEQ ID NO: 24 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR2 contains SEQ ID NO: 25 or differs from SEQ ID NO: 25 by one or two substitutions, deletions, or additions, and The amino acid sequence of H-CDR3 contains SEQ ID NO: 26 or differs from SEQ ID NO: 26 by one or two substitutions, deletions, or additions.
11. The anti-HIV-1 antibody according to any one of claims 1 to 6 or 8, wherein the amino acid sequence of H-CDR1 comprises SEQ ID NO: 27 or differs from SEQ ID NO: 27 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR2 contains SEQ ID NO: 28 or differs from SEQ ID NO: 28 by one or two substitutions, deletions, or additions, and The amino acid sequence of H-CDR3 contains SEQ ID NO: 29 or differs from SEQ ID NO: 29 by one or two substitutions, deletions, or additions.
12. The anti-HIV-1 antibody according to any one of claims 1 to 6 or 9, wherein the amino acid sequence of H-CDR1 comprises SEQ ID NO: 30 or a sequence differing from SEQ ID NO: 30 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR2 contains SEQ ID NO: 31 or differs from SEQ ID NO: 31 by one or two substitutions, deletions, or additions, and The amino acid sequence of H-CDR3 contains SEQ ID NO: 32 or differs from SEQ ID NO: 32 by one or two substitutions, deletions, or additions.
13. The anti-HIV-1 antibody according to any one of claims 1 to 6, wherein the amino acid sequence of L-CDR1 comprises SEQ ID NO: 15 or differs from SEQ ID NO: 15 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR2 contains SEQ ID NO: 16 or differs from SEQ ID NO: 16 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR3 contains SEQ ID NO: 17 or differs from SEQ ID NO: 17 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR1 contains SEQ ID NO: 24 or differs from SEQ ID NO: 24 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR2 contains SEQ ID NO: 25 or differs from SEQ ID NO: 25 by one or two substitutions, deletions, or additions, and The amino acid sequence of H-CDR3 contains SEQ ID NO: 26 or differs from SEQ ID NO: 26 by one or two substitutions, deletions, or additions.
14. The anti-HIV-1 antibody according to any one of claims 1 to 6, wherein the amino acid sequence of L-CDR1 comprises SEQ ID NO: 18 or a sequence differing from SEQ ID NO: 18 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR2 contains SEQ ID NO: 19 or differs from SEQ ID NO: 19 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR3 contains SEQ ID NO: 20 or differs from SEQ ID NO: 20 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR1 contains SEQ ID NO: 27 or differs from SEQ ID NO: 27 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR2 contains SEQ ID NO: 28 or differs from SEQ ID NO: 28 by one or two substitutions, deletions, or additions, and The amino acid sequence of H-CDR3 contains SEQ ID NO: 29 or differs from SEQ ID NO: 29 by one or two substitutions, deletions, or additions.
15. The anti-HIV-1 antibody according to any one of claims 1 to 6, wherein the amino acid sequence of L-CDR1 comprises SEQ ID NO: 21 or differs from SEQ ID NO: 21 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR2 contains SEQ ID NO: 22 or differs from SEQ ID NO: 22 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR3 contains SEQ ID NO: 23 or differs from SEQ ID NO: 23 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR1 contains SEQ ID NO: 30 or differs from SEQ ID NO: 30 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR2 contains SEQ ID NO: 31 or differs from SEQ ID NO: 31 by one or two substitutions, deletions, or additions, and The amino acid sequence of H-CDR3 contains SEQ ID NO: 32 or differs from SEQ ID NO: 32 by one or two substitutions, deletions, or additions.
16. The anti-HIV-1 antibody according to any one of claims 1 to 6, wherein the light chain of the antibody comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO:
3.
17. The anti-HIV-1 antibody according to any one of claims 1 to 6, wherein the heavy chain of the antibody comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO:
6.
18. The anti-HIV-1 antibody according to any one of claims 1 to 6, wherein the light chain of the antibody comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, and the heavy chain of the antibody comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO:
6.
19. The anti-HIV-1 antibody according to any one of the preceding claims, wherein the antibody is a monoclonal antibody or a recombinant antibody.
20. The anti-HIV-1 antibody according to any one of the preceding claims, wherein the antibody is an antibody fragment.
21. The anti-HIV-1 antibody according to claim 20, wherein the antibody fragment is selected from variable fragments (Fv), single-chain Fv (scFv), bispecific antibodies (sc(Fv)2), single-chain antibodies, single-domain antibodies, Fab fragments, F(ab')2 fragments, Fab' fragments, disulfide-linked Fv (dsFv), chemically conjugated Fv (ccFv), biantibodies, anti-idiotype (anti-Id) antibodies, affinity molecules, nanobodies, and monoantibodies.
22. The anti-HIV-1 antibody according to any one of the preceding claims, wherein the antibody comprises a constant region of mouse IgG1 or mouse IgG2a.
23. The anti-HIV-1 antibody according to any one of the preceding claims, wherein the antibody is bound to a solid support.
24. A cell comprising an anti-HIV-1 antibody as described in any of the preceding claims.
25. A nucleic acid comprising a nucleotide sequence encoding an anti-HIV-1 antibody according to any one of claims 1 to 20; a promoter operatively linked to the nucleotide sequence; and a selection marker.
26. A cell comprising the nucleic acid according to claim 25.
27. A composition comprising an anti-HIV-1 antibody according to any one of claims 1 to 20; and a solid support, wherein the anti-HIV-1 antibody is covalently or non-covalently bound to the solid support.
28. The composition of claim 27, wherein the solid support comprises the solid phase of particles, beads, membranes, surfaces, polypeptide chips, microtiter plates, and chromatographic columns.
29. A kit for detecting the presence of HIV-1 in a sample, the kit comprising at least one anti-HIV-1 antibody according to any one of claims 1 to 23 and a solid support, wherein the at least one anti-HIV-1 antibody is covalently or non-covalently bound to the solid support.
30. An anti-HIV-1 antibody, characterized in that... The anti-HIV-1 antibody specifically binds to an epitope of the HIV-1 p24 protein, the epitope of which contains the amino acid sequence of SEQ ID NO:
33.
31. The anti-HIV-1 antibody according to claim 30, wherein the amino acid sequence of L-CDR1 comprises SEQ ID NO:21 or differs from SEQ ID NO:21 by one or two substitutions, deletions, or additions. The amino acid sequence of L-CDR2 contains SEQ ID NO: 22 or differs from SEQ ID NO: 22 by one or two substitutions, deletions, or additions, and The amino acid sequence of L-CDR3 contains SEQ ID NO: 23 or differs from SEQ ID NO: 23 by one or two substitutions, deletions, or additions.
32. The anti-HIV-1 antibody according to any one of claims 30 to 31, wherein the amino acid sequence of H-CDR1 comprises SEQ ID NO: 30 or differs from SEQ ID NO: 30 by one or two substitutions, deletions, or additions. The amino acid sequence of H-CDR2 contains SEQ ID NO: 31 or differs from SEQ ID NO: 31 by one or two substitutions, deletions, or additions, and The amino acid sequence of H-CDR3 contains SEQ ID NO: 32 or differs from SEQ ID NO: 32 by one or two substitutions, deletions, or additions.
